Finale Programme
WORK 41st Nordic Congress
CLOSER. of Obstetrics and 1 Gynecology REACH Odense, June 10th to 13th 2018 FURTHER. www. nfog2018.dk Protector Protector of the 41st Nordic Congress of Obstetrics and Gynecology NFOG2018
2
Her Royal Highness Crown Princess Mary CONTENT WELCOME MESSAGES 4 REGISTRATION 6 3 GENERAL INFORMATION 7 OFFICIAL NETWORKING EVENTS 8 SPEAKER INFORMATION 12 FELLOWSHIP PROGRAMME 12 NFOG APP 14 PRE-CONGRESS CONFERENCE 14 PRE-CONGRESS WORKSHOPS 16 PROGRAMME 19 PROGRAMME AT A GLANCE 32 POSTERS 34 SPEAKER INDEX 41 INSTRUCTIONS FOR ORAL AND POSTER PRESENTERS 42 COMMITTEES 44 INDUSTRY SUPPORTED SYMPOSIA 46 CONGRESS SUPPORTERS 49 DIRECTORY OF EXHIBITORS 50 VENUE (FLOORPLAN) 52 SLEEP WELL 55 WELCOME MESSAGES
Greetings everyone!
On behalf of the NFOG Board it is a great pleasure to welcome you to the 41st NFOG Congress in Odense, Denmark, June 10th to 13th 2018. We hope that you will embrace the special relaxed Nordic atmosphere at the congress, where science and important issues on women’s health are presented and discussed during the scientific sessions and workshops. The importance of networking must remain in focus for all of us and is recognized in the social programme.
It is an enormous task to arrange this important meeting and the NFOG board is most grateful to colleagues in the Scientific Committee of NFOG, and especially to the local Organising Committee headed by Congress President Bjarne Rønde Kristensen for their fantastic work.
Karen Wøjdemann President NFOG Karen R. Wøjdemann 4
Welcome to Odense
Dear Colleagues
As Obstetricians and Gynecologists, we share the privilege of caring for Women’s Health and Wellbeing, from the cradle to the grave. The Nordic Community within our specialty is unique internationally, as we have cross-border opportunities for Clinical and Scientific cooperation in Innovation and Research.
Accordingly, it is our great honour to welcome you to the 41st NFOG Congress.
The Venue is The Odeon in the Centre of Odense, a brand new; purpose built Conference Centre, which Odense City Council commissioned the day after we won the nomination to host the Nordic Congress in October 2013. Since that day, the Local Organising and Scientific Committee, together with the Board and the Scientific Committee of the NFOG, have been working closely to prepare for the Congress.
The Congress brings together practitioners and specialists, not only from the Nordic countries, but from all over the world, and the Scientific Committee has prepared an exciting and dynamic programme to advance knowledge, build partnerships and exchange ideas.
We are grateful for, and impressed by the number and quality of the free communications submitted orally or as post- er presentations. The posters will be available to view throughout the Congress.
The NFOG Congress has existed for more than 80 years, but for the last 10 years or so, has focussed on Global Health, 5 with increasing participation from colleague’s out with the Nordic countries. Innovatively, in cooperation with the Local Municipality of Odense who has been incredibly welcoming and helpful, we have broadened the Congress to include the local community, with a number of public lectures in the City.
During your stay in Denmark, I hope you will take the time to experience not only the City of Odense, but also other parts of our beautiful Island of Funen.
The Nordic Congress is the preeminent meeting place for us all. Embrace this opportunity to meet old friends and make new acquaintance’s within the Nordic community and the rest of the world. Join the get-together on Sunday at 19:30, the Welcome and Opening Session Monday at 09:00, the Guided tours and River Cruise Monday at 19:00, the Run for Women’s Health and Rights on Tuesday at 6:30 and walk with us from The Odeon at 18:30 to the Congress Dinner on Tuesday at 19:30.
Enjoy the Congress and the City of Odense.
Welcome!
Bjarne Rønde Kristensen Congress President Bjarne Rønde Kristensen REGISTRATION NFOG2018 Early Regular High (until April 1st 2018) (April 2nd – May 9th 2018) (May 10th 2018 - )
Members/Specialists 4.500 DKK 5.700 DKK 6.700 DKK
Midwifes/Nurses/Others 4.500 DKK 5.700 DKK 6.700 DKK
Student/Trainees 2.900 DKK 3.600 DKK 4.000 DKK
One day fee: Members/Specialist 1.750 DKK 2.200 DKK 2.500 DKK
One day fee: Midwifes/Nurses/Others 1.750 DKK 2.200 DKK 2.500 DKK
One day fee: Student/Trainees 1.100 DKK 1.500 DKK 1.750 DKK
Congress Dinner -accompanying person 950 DKK 950 DKK 950 DKK
Pre congress workshops The workshops are allocated on a first come, first served basis. Includes sandwich and beverage If you are signed up for the congress, the price per workshop is 350 DKK. 6 If you are not signed up the congress, the price per workshop is 700 DKK.
Entitlements Delegates’ registration includes: Badge and congress documents + Participation in the Scientific Programme + Access to the exhibition and poster area + Lunch and coffee breaks + Welcome Reception + Congress Dinner
Registration takes place next to the bar in the foyer in ODEON. Registration hours: Sunday June 10th 2018 from 16:00 to 20:00 Monday June 11th 2018 from 07:30 Tuesday June 12th 2018 from 08:30 Wednesday June 13th 2018 from 08:30 GENERAL INFORMATION NFOG2018 Early Regular High (until April 1st 2018) (April 2nd – May 9th 2018) (May 10th 2018 - ) Congress Venue ODEON, Odeons Kvarter 1, 5000 Odense Members/Specialists 4.500 DKK 5.700 DKK 6.700 DKK Telephone: +45 6614 7800 Midwifes/Nurses/Others 4.500 DKK 5.700 DKK 6.700 DKK https://odeonodense.dk
Student/Trainees 2.900 DKK 3.600 DKK 4.000 DKK Meeting rooms Locations for the sessions are displayed on screens at the venue. One day fee: Members/Specialist 1.750 DKK 2.200 DKK 2.500 DKK
One day fee: Midwifes/Nurses/Others 1.750 DKK 2.200 DKK 2.500 DKK Conference documents and badges should be collected on-site, at the registration desk. Name badges must be worn during sessions and events. One day fee: Student/Trainees 1.100 DKK 1.500 DKK 1.750 DKK
Congress Dinner -accompanying person 950 DKK 950 DKK 950 DKK Languages The official conference language is English. Pre congress workshops The workshops are allocated on a first come, first served basis. Includes sandwich and beverage If you are signed up for the congress, the price per workshop is 350 DKK. Online program book If you are not signed up the congress, the price per workshop is 700 DKK. The full program book will be available on the NFOG2018 website and on the APP. 7
Internet Service Free Wifi is available for congress participants during the venue.
Mobile phones All mobile phones must be on silent mode during sessions.
Meals First meal to be served is at the Get Together June 10th 2018 at 19:30 in Odeon´s foyer. Coffee breaks and lunch´s will be in the exhibition areas and at Lunch Symposia´s. The Congress Dinner will be at DOK5000.
NFOG General Assembly June 12th from 16:00 – 17:30 in meeting room 107, 1st floor.
Smoking is allowed at outdoor areas only.
Safety and security Please do not leave bags or suitcases unattended at any time at the venue.
Wardrobe There is a wardrobe in the basement. Use of the wardrobe is at your own risk. OFFICIAL NETWORKING EVENTS Get together Sunday June 10th 2018 at 19:30 in the foyer of ODEON The Get together offers rich opportunity to network and get acquainted with col- 8 leagues from your own and other countries. The menu will be prepared by organic products from Funen and this evening will be informal, relaxed and fun and will include live music by the Nova Love Band.
Welcome and Opening Session Monday June 11th 2018, at 09:00. Location: Store Sal • ”Tågen letter” Carl Nielsen. Soloist´: Joost Schelling, harp & to be announced, flute. • ”Solen er så rød mor” Melodi: Carl Nielsen. Lyrics: Harald Bergstedt. Accompaniment: Mikkel Burchardt. Soloist´: Dorete F. Munck • Koncertpolka for to violiner (1863. ) H.C. Lumbye. Violins: Stefan og Alexander Burchardt. Piano: Mikkel Burchardt.
Speakers Dinner Monday June 11th 2018, at 19:30. Location: Galleri Galschiøt Speakers dinner is for all invited speakers. The dinner is at Gallery Galschiøt, Banevænget 22, 5270 Odense N. We have arranged transportation. Departure from ODEON (buses) at 19:10 and arrival at Gallery Galschiøt at 19:25. Departure from Gallery Galschiøt at 23:00. 1st (un)official NFOG 5K run : Run for women´s global health and rights Tuesday June 12th at 6:30
Dear colleagues and running friends.
Bring your running gear to Odense and join us for the 1st (un) official NFOG run in beautiful Odense.
The run starts Tuesday June 12th 2018 at 06:30.
The course is along the beautiful creek in the middle of Odense and is an easy 5K track. (Exact length 5.2 km). We will be passing beautiful parks, H.C. Andersen decorations, and Odense Zoo with a view to camels and tigers. The start and ending point will be really close to the center of Odense, only about 500m from the Hotels.
Further information will follow on the www.nfog.dk and Facebook.
Route: ruteplanner.iform.dk/rute/odense-c/nfog-morgentur-52-km 9 Registration: There will be no formal registration; just be at the starting area at 06:15. Start: Nelle’s Café Kunstbygningen Filosoffen, Filosofgangen 30 C, 5000 Odense C Timing: There will be no official timing, bring your own watch and mobile phone. Refreshments: There will be a small juice for the participants.
For questions do not hesitate to ask one of the organisers: Lise Lotte T.Andersen: [email protected] Dorethe F. Munck: [email protected] Kirsten Jochumsen: [email protected]
Public Mettings in Odense During the congress, a number of lectures will be held in the centre of the city in collaboration with the Odense-based branch of Danish Women’s Society. The lectures aim to bring the professional profile of the congress into a citizen-oriented context, thus creating a space for discussion of both conventional and controversial themes in regards to obstetrics and gynaecology, all in the context of gender equality. Congress dinner June 12th 2018 at 19:30 at DOK5000, Havnegade 20 5000 Odense C
We meet in ODEON’s foyer at 18:45 and take a brisk After the dinner, drinks are at your own cost. walk down to DOK5000 via “Byen Bro”. The walk is Music by the band “Okholm og Pistolerne”. 10 about 2 km and will be guided by young dancers from After a pleasant evening with fun and community Odense Ballet Academy. singing there will be barbecue in the tent outside DOK5000 between 24:00 to 01:00. If you prefer to take a taxi “Taxa Fyn” can be contacted on telephone +45 6615 4415. No transportation is arranged back to the hotels. If you want a taxi “Taxa Fyn” can be contacted on We start with aperitif and appetizers in the tent just telephone +45 6615 4415. outside DOK5000. At 20:00 The Congress Dinner begins inside DOK5000. The dinner will be served at the tables, and there will be special buffets for vegetarians / ve- gans and allergy sufferers. Guided tours and River Cruise
Visit and guided tour of the Hans Christian Andersen Museum When: Monday June 11th from 7 pm to 8 pm. Meeting place: The Hans Christian Andersen Museum, Claus Bergs Gade 11 - we meet at the entrance. Registration is necessary. You register by emailing [email protected] or at the tourist info stand in Odeon.
Odense River Cruise When: Monday June 11th from 7 pm to 8 pm. Please note that the boat sails at 7 pm. sharp. Meeting place: Odense River Cruise, Filosofgangen 30. Registration is necessary. You register by emailing [email protected] or at the tourist info stand in Odeon. There is a limit of 85 passengers on the river cruise.
11 In the Footsteps of Hans Christian Andersen - guided tour When: Monday June 11th from 7 pm to 8 pm. Meeting place: ODEON Conference Center, Odeons Kvarter 1 Registration is necessary. You register by emailing [email protected] or at the tourist info stand in Odeon.
For further information, see the NFOG2018 website: nfog2018.dk
Trainee Dinner 7 pm Monday the 11th of June
Join your Nordic trainee colleagues for a fun dinner with interesting relevant talks. Sign up today as there is limited seating in the restaurant. You can sign up in Bayer’s exhibition stand. Where: Cafe’ Cuckoo’s Nest, Vestergade 73, 5000 Odense. The event is sponsored by Bayer. SPEAKER INFORMATION
Instructions for PowerPoint (/Prezi presentations) We kindly ask you to follow the instructions to ensure a successful and smooth progress of the timetable.
In each auditorium there is a laptop available (Windows or Apple) which you are kindly requested to use. Please hand in your presentation in the Speakers PREP room: Room number 108 at the first floor in Odeon. Please bring your presentation on a USB stick saved in a version compatible with PowerPoint version 10 and please make sure the file is with your full name on! The presentations will be at widescreen format 16x9. Professional technicians will help you to transfer your presentation on the provided computers. In order to avoid queues and delays you must contact the technicians in the Speakers PREP room preferably the day before your presentation or in the morning no later than two hours before your presentation.
The technicians will be present on June 10th 2018 at 18:00 to 20:00 to assist speakers for Monday morning as well as during all days of the congress. If you are going to make a Prezi presentation we would like to know in advance, so send us an email.
If you prefer to use your own laptop for special reasons you should bring your own adaptor as well. In case of doubt, contact a local assistant.
12
FELLOWSHIP PROGRAMME
A Nordic trainee exchange fellowship has taken place for the first time in relation to this year’s NFOG Congress in Odense. All trainees in Obstetrics and Gynecology have been invited to participate in the exchange. Trainees from different Nordic countries have visited different departments in Denmark over two days, and have been a part of the daily routine of a Danish doctor. A Danish host from each department was appointed, and the Nordic trainee was given the opportunity to stay in their home and experience Danish culture.
The aim of the fellowship was to strengthen collaboration and to expand the Nordic network within obstetrics and gynecology. We hope that the Nordic colleagues and their host hospitals had inspiring and interesting days together in Denmark. 13
FELLOWSHIP PROGRAMME NFOG2018 APP
Download the NFOG 2018 app by scanning the QR code or by searching for “NFOG 2018” on either App Store or Google Play.
14
PRE-CONGRESS CONFERENCE
The fifth Nordic Conference on Endometriosis is this time held as a pre-congress meeting to NFOG2018.
The Conference will be held from Friday June 8th until Sunday June 10th here in Odense with venue at the University of Southern Denmark - Auditorium 25, Winsløws Vej 25, 5000 Odense C. www.nce2018.dk
et’s end this tragedy.” this end et’s L Foundation.
tions are available. are tions " patron of Maternity Maternity of patron
of Denmark has been been has Denmark of cost-effective interven- cost-effective
And supported by: supported And
Crown Princess Mary Mary Princess Crown #safedeliveryapp #maternityfoundation @MaternityF #maternityfoundation #safedeliveryapp what to do and small, and do to what
Since 2010, H.R.H. 2010, Since
For more information go to www.safedelivery.org to go information more For
preventable. We know We preventable. Produced by: Produced
DENMARK newborn deaths are are deaths newborn
PRINCESS MARY OF OF MARY PRINCESS most maternal and maternal most
implementation settings. implementation Unacceptable because Unacceptable H.R.H. CROWN CROWN H.R.H.
trainings. We consolidate learning and results across the different different the across results and learning consolidate We trainings. unacceptable.
, technical support, our implementation toolbox and with with and toolbox implementation our support, technical , App
give life is a tragedy and tragedy a is life give The Safe Delivery App is developed by: by: developed is App Delivery Safe The
tions of the the of tions adapta localized with s partner supports - Foundation
“That women risk life to to life risk women “That
Maternity at located - Center Competency mHealth he T Gates Foundation and a number of non-disclosed partners. non-disclosed of number a and Foundation Gates
The Safe Delivery App is funded by MSD for Mothers, the Bill & Melinda Melinda & Bill the Mothers, for MSD by funded is App Delivery Safe The
et’s end this tragedy.” this end et’s L Foundation. organizations. non-governmental
tions are available. are tions " patron of Maternity Maternity of patron
ting partners in each country, e.g. ministries of health and and health of ministries e.g. country, each in partners ting
Gynecologists).
of Denmark has been been has Denmark of
cost-effective interven- cost-effective
- implemen key with partnership in tries coun middle-income
And supported by: supported And cologists), and ACOG (the American Congress of Obstetricians and and Obstetricians of Congress American (the ACOG and cologists),
Crown Princess Mary Mary Princess Crown #safedeliveryapp #maternityfoundation @MaternityF #maternityfoundation #safedeliveryapp what to do and small, and do to what
App Store and Google Play and will be rolled out in low- and and low- in out rolled be will and Play Google and Store App
Since 2010, H.R.H. 2010, Since
- Gynae and Obstetricians of College Royal (the RCOG Obstetrics), For more information go to www.safedelivery.org to go information more For
preventable. We know We preventable.
Produced by: Produced
The Safe Delivery App is freely available for download at the the at download for available freely is App Delivery Safe The DENMARK in Obestrics), FIGO (the International Federation of Gynecology and and Gynecology of Federation International (the FIGO Obestrics), in newborn deaths are are deaths newborn
PRINCESS MARY OF OF MARY PRINCESS partners most maternal and maternal most (the World Health Organization) as well as ALSO (Advanced Life Support Support Life (Advanced ALSO as well as Organization) Health World (the
implementation settings. implementation
Unacceptable because Unacceptable H.R.H. CROWN CROWN H.R.H. The Safe Delivery App is based on international guidelines from WHO WHO from guidelines international on based is App Delivery Safe The
trainings. We consolidate learning and results across the different different the across results and learning consolidate We trainings. unacceptable.
, technical support, our implementation toolbox and with with and toolbox implementation our support, technical , App
give life is a tragedy and tragedy a is life give The Safe Delivery App is developed by: by: developed is App Delivery Safe The
responsible for all scientific testing. testing. scientific all for responsible
tions of the the of tions adapta localized with s partner supports - Foundation implementing
“That women risk life to to life risk women “That
sity of Copenhagen and University of Southern Denmark have been been have Denmark Southern of University and Copenhagen of sity
Maternity at located - Center Competency mHealth he T Gates Foundation and a number of non-disclosed partners. non-disclosed of number a and Foundation Gates
- Univer from Sørensen Lund Bjarke Dr. and Lund Stine Dr. Specialists The Safe Delivery App is funded by MSD for Mothers, the Bill & Melinda Melinda & Bill the Mothers, for MSD by funded is App Delivery Safe The
organizations. non-governmental
ting partners in each country, e.g. ministries of health and and health of ministries e.g. country, each in partners ting Gynecologists).
ograms. pr health sustainable implementing all for free
- implemen key with partnership in tries coun middle-income cologists), and ACOG (the American Congress of Obstetricians and and Obstetricians of Congress American (the ACOG and cologists),
countries by developing innovative maternal health solutions and and solutions health maternal innovative developing by countries
App Store and Google Play and will be rolled out in low- and and low- in out rolled be will and Play Google and Store App - Gynae and Obstetricians of College Royal (the RCOG Obstetrics),
The Safe Delivery App is freely available for download at the the at download for available freely is App Delivery Safe The to reduce maternal and newborn mortality in low- and middle-income middle-income and low- in mortality newborn and maternal reduce to
in Obestrics), FIGO (the International Federation of Gynecology and and Gynecology of Federation International (the FIGO Obestrics), in
partners
TTENDANTS TTENDANTS A BIRTH
(the World Health Organization) as well as ALSO (Advanced Life Support Support Life (Advanced ALSO as well as Organization) Health World (the
Maternity Foundation is a Danish development organization that aims aims that organization development Danish a is Foundation Maternity
The Safe Delivery App is based on international guidelines from WHO WHO from guidelines international on based is App Delivery Safe The for Available
A MOBILE HEALTH TOOL FOR SKILLED SKILLED FOR TOOL HEALTH MOBILE A
of Southern Denmark. Denmark. Southern of
responsible for all scientific testing. testing. scientific all for responsible
implementing implementing
THE SAFE DELIVERY APP DELIVERY SAFE THE
oundation, the University of Copenhagen and the University University the and Copenhagen of University the oundation, F Maternity sity of Copenhagen and University of Southern Denmark have been been have Denmark Southern of University and Copenhagen of sity
- Univer from Sørensen Lund Bjarke Dr. and Lund Stine Dr. Specialists
The Safe Delivery App was developed in a collaboration between between collaboration a in developed was App Delivery Safe The
Partners
ograms. pr health sustainable implementing all for free
countries by developing innovative maternal health solutions and and solutions health maternal innovative developing by countries
to reduce maternal and newborn mortality in low- and middle-income middle-income and low- in mortality newborn and maternal reduce to
TTENDANTS TTENDANTS A BIRTH
Maternity Foundation is a Danish development organization that aims aims that organization development Danish a is Foundation Maternity Available for for Available
A MOBILE HEALTH TOOL FOR SKILLED SKILLED FOR TOOL HEALTH MOBILE A of Southern Denmark. Denmark. Southern of
THE SAFE DELIVERY APP DELIVERY SAFE THE
oundation, the University of Copenhagen and the University University the and Copenhagen of University the oundation, F Maternity
The Safe Delivery App was developed in a collaboration between between collaboration a in developed was App Delivery Safe The Partners
The Safe Delivery App leverages the growing ubiquity of mobile phones to provide life-saving information and
life life guidance through easy-to-understand animated instruction
guidance. platform. learning childbirth. s clinical content. clinical s App’
for them. for videos, action cards and drug lists. Once downloaded, The
es and access to the the to access and es procedur and easy-to-understand easy-to-understand and complications in pregnancy and and pregnancy in complications experience based on the the on based experience
proper guidance and training training and guidance proper LIVES CAN BE
tuitive tuitive in provide videos practical list, drug cards, action clinical modules on managing managing on modules clinical
learning learning motivational Safe Delivery App is stored on the smartphone and does
providing and areas e remot
Every year, around 300,000 The safe The Safe Delivery App leverages the growing ubiquity of Animated instruction instruction Animated videos, contains module Each App structured around 10 10 around structured App Individualized, highly highly Individualized, is reaching health workers in in workers health reaching is giving not require internet access. The App has been adapted to a
women die from pregnancy mobile phones to provide life-saving information and
fessionals. The main challenge challenge main The fessionals. guidance through easy-to-understand animatednumber instruction of local languages.
-
attended by skilled health pro health skilled by attended or childbirth-related com- LIVES CAN BE videos, action cards and drug lists. Once downloaded, The It is crucial that all births are are births all that crucial is It SAVED Safe Delivery App is stored on the smartphone and does
NFOG2018 APP plications.Every year, That around is more 300,000 than The safe The App was tested in a randomized controlled trial across deaths are preventable. are deaths not require internet access. The App has been adapted to a
women die fromdie pregnancy 78 health facilities in Ethiopia in 2014. The results showed a
800 women every single day. The Safe Delivery App empowers skilled birth attendants to number of local languages. Most maternal and newborn newborn and maternal Most Delivery app
No or childbirth-related com- SAVEDprovide a safer birth for mothers and newborns - everywhere. remarkable increase in the skills and knowledge level of the plications. That is more than The App was tested in a randomized controlled trial across
and death. death. and More than 5 million babies also The App is a smartphone application that provides skilled birth health workers working with the App: their ability to handle
800 women every single day. The Safe Delivery App empowers skilled birth attendants to 78 health facilities in Ethiopia in 2014. The results showed a make the difference between life life between difference the make Delivery app postnatal bleeding and to resuscitate a newborn more than die from delivery complications attendants with direct and instant access to evidence-based and
should should provide a safer birth for mothers and newborns - everywhere. remarkable increase in the skills and knowledge level of the management and treatment can can treatment and No management or withinMore the than first 5 million days babies or weeksalso Theup-to-date App is a smartphone clinical application guidelines that onprovides Basic skilled Emergency birth Obstetric and health workers working with the App: theirdoubled ability to handle after 12 months of using the App.
deaths can be prevented: timely timely prevented: be can deaths of life.die Today, from delivery maternal complications mortality attendantsNeonatal with Care.direct andIt can instant serve access as toa trainingevidence-based tool both and in pre- and postnatal bleeding and to resuscitate a newborn more than
of these maternal and newborn newborn and maternal these of or within the first days or weeks up-to-date clinical guidelines on Basic Emergency Obstetric and doubled after 12 months of using the App. ence tool. ence refer on-the-job most remote areas with a powerful powerful a with areas remote most Woman becoming orphaned. But most most But orphaned. becoming is a leading cause of children in-service training, and equips skilled birth attendants even in the
of life. Today, maternal mortality Neonatal Care. It can serve as a training tool both in pre- and in-service training, and equips skilled birth attendants even in the the in even attendants birth skilled equips and training, in-service is a leading cause of children children of cause leading a is
Woman becoming orphaned.Woman But most most remote areas with a powerful on-the-job reference tool. is a leading cause of children in-service training, and equips skilled birth attendants even in the
Neonatal Care. It can serve as a training tool both in pre- and and pre- in both tool training a as serve can It Care. Neonatal
of life. Today, maternal mortality mortality maternal Today, life. of of thesebecoming maternal orphaned. and newborn But most most remote areas with a powerful on-the-job reference tool. life life
up-to-date clinical guidelines on Basic Emergency Obstetric and and Obstetric Emergency Basic on guidelines clinical up-to-date or within the first days or weeks weeks or days first the within or
doubled after 12 months of using the App. the using of months 12 after doubled
guidance. platform. learning childbirth.
App’s clinical content. clinical App’s
of these maternal and newborn them. for
and easy-to-understand easy-to-understand and the to access and procedures and pregnancy in complications experience based on the the on based experience deaths can be prevented: timely training and guidance proper
videos provide intuitive intuitive provide videos practical list, drug cards, action managing on modules clinical
motivational learning learning motivational attendants with direct and instant access to evidence-based and and evidence-based to access instant and direct with attendants die from delivery complications complications delivery from die
providing and areas remote postnatal bleeding and to resuscitate a newborn more than than more newborn a resuscitate to and bleeding postnatal
Animated instruction instruction Animated videos, contains module Each 10 around structured App
Individualized, highly highly Individualized,
managementdeaths can and be prevented: treatment timely can in workers health reaching is giving fessionals. The main challenge challenge main The fessionals.
The App is a smartphone application that provides skilled birth birth skilled provides that application smartphone a is App The More than 5 million babies also also babies million 5 than More
health workers working with the App: their ability to handle handle to ability their App: the with working workers health should
-
management and treatment canpro health skilled by attended
should No are births all that crucial is It
provide a safer birth for mothers and newborns - everywhere. everywhere. - newborns and mothers for birth safer a provide make the difference between life deaths are preventable. are deaths die die
remarkable increase in the skills and knowledge level of the the of level knowledge and skills the in increase remarkable make the difference between life
Most maternal and newborn newborn and maternal Most
Delivery app Delivery to attendants birth skilled empowers App Delivery fe Sa The
800 women every single day. single every women 800
78 health facilities in Ethiopia in 2014. The results showed a a showed results The 2014. in Ethiopia in facilities health 78
and death.and death. death. and
make the difference between life life between difference the make
management and treatment can can treatment and management should
plications. That is more than than more is That plications. ed in a randomized controlled trial across across trial controlled randomized a in ed test was App The
SAVED timely prevented: be can deaths
Most maternal and newborn newborn and maternal these of
on-the-job reference tool. reference on-the-job powerful a with areas remote most becoming orphaned. But most most But orphaned. becoming -
or childbirth-related com childbirth-related or Most maternal and newborn
in-service training, and equips skilled birth attendants even in the the in even attendants birth skilled equips and training, in-service is a leading cause of children children of cause leading a is
die Woman languages. local of number Neonatal Care. It can serve as a training tool both in pre- and and pre- in both tool training a as serve can It Care. Neonatal
deaths are preventable. mortality maternal Today, life. of 15
up-to-date clinical guidelines on Basic Emergency Obstetric and and Obstetric Emergency Basic on guidelines clinical up-to-date
women die from pregnancy pregnancy from die women die weeks or days first the within or
doubled after 12 months of using the App. the using of months 12 after doubled deaths are preventable.
attendants with direct and instant access to evidence-based and and evidence-based to access instant and direct with attendants die from delivery complications complications delivery from die postnatal bleeding and to resuscitate a newborn more than than more newborn a resuscitate to and bleeding postnatal
not require internet access. The App has been adapted to a a to adapted been has App The access. internet require not It is crucial that all births are
The App is a smartphone application that provides skilled birth birth skilled provides that application smartphone a is App The
More than 5 million babies also also babies million 5 than More health workers working with the App: their ability to handle handle to ability their App: the with working workers health
No No
The safe safe The 300,000 around year, Every
provide a safer birth for mothers and newborns - everywhere. everywhere. - newborns and mothers for birth safer a provide
remarkable increase in the skills and knowledge level of the the of level knowledge and skills the in increase remarkable It is crucial that all births are
Delivery app Delivery attended by skilled health pro- The Safe Delivery App empowers skilled birth attendants to to attendants birth skilled empowers App Delivery Safe The 800 women every single day. single every women 800 ed on the smartphone and does does and smartphone the on ed stor is App Delivery Safe 78 health facilities in Ethiopia in 2014. The results showed a a showed results The 2014. in Ethiopia in facilities health 78
LIVES CAN BE BE CAN LIVES than more is That plications. The App was tested in a randomized controlled trial across across trial controlled randomized a in tested was App The
SAVED
-
fessionals. The main challenge com childbirth-related or
e downloaded, The The downloaded, e Onc lists. drug and cards action videos, videos, attended by skilled health pro-
languages. local of number
women die from pregnancy pregnancy from die women
not require internet access. The App has been adapted to a a to adapted been has App The access. internet require not
The safe safe The is reaching health workers in 300,000 around year, Every Delivery App is stored on the smartphone and does does and smartphone the on stored is App Delivery Safe o-understand animated instruction instruction animated o-understand easy-t through guidance giving
fessionals. TheBE mainCAN challengeLIVES App structured around 10 Each module contains videos, Animated instruction Individualized, highly action cards and drug lists. Once downloaded, The The downloaded, Once lists. drug and cards action videos,
guidance through easy-to-understand animated instruction instruction animated easy-to-understand through guidance
remote areas and providing
vide life-saving information and and information life-saving vide pro to phones mobile
clinical modules on managing action cards, drug list, practical videos provide intuitive motivational learning
mobile phones to provide life-saving information and and information life-saving provide to phones mobile
is reaching health workers in
The Safe Delivery App leverages the growing ubiquity of of ubiquity growing the givingleverages App Delivery Safe The
proper guidance and training complications in pregnancyApp and structured procedur aroundes and 10 access to the Eachand module easy-to-understand contains videos, experienceAnimated based on instruction the Individualized, highly The Safe Delivery App leverages the growing ubiquity of of ubiquity growing the leverages App Delivery Safe The PRE-CONGRESS remotfore areas them. and providing childbirth. clinical moduleslearning on platform.managing actionguidance. cards, drug list, practical App’s clinical videos content. provide intuitive motivational learning life proper guidance and training complications in pregnancy and procedures and access to the and easy-to-understand experience based on the CONFERENCE for them. childbirth. learning platform. guidance. App’s clinical content. Partners The Safe Delivery App was developed in a collaboration between Maternity Foundation, the University of Copenhagen and the University THE SAFE DELIVERY APP life of Southern Denmark. Available for A MOBILE HEALTH TOOL FOR SKILLED Maternity Foundation is a Danish development organization that aims BIRTH ATTENDANTS to reduce maternal and newborn mortality in low- and middle-income countries by developing innovative maternal health solutions and free for all implementing sustainable health programs. Specialists Dr. Stine Lund and Dr. Bjarke Lund Sørensen from Univer- implementing sity of Copenhagen and University of Southern Denmark have been responsible for all scientific testing.
The Safe Delivery App is based on international guidelines from WHO partners (the World Health Organization) as well as ALSO (Advanced Life Support The Safe Delivery App is freely available for download at the in Obestrics), FIGO (the International Federation of Gynecology and Partners App Store and Google Play and will be rolled out in low- and Obstetrics), RCOG (the Royal College of Obstetricians and Gynae- middle-income countries in partnership with key implemen- cologists), and ACOG (the American Congress of Obstetricians and ting partners in each country, e.g. ministries of health and Gynecologists). The Safe Delivery App was developed in a collaboration between non-governmental organizations. The Safe Delivery App is funded by MSD for Mothers, the Bill & Melinda The mHealth Competency Center - located at Maternity Gates Foundation and a number of non-disclosed partners. Maternity Foundation, the University of Copenhagen and the University“That women risk life to THE SAFE Foundation - supports partners withDELIVERY localized adapta tions of the APP give life is a tragedy and App, technical support, our implementation toolbox and with The Safe Delivery App is developed by: of Southern Denmark. unacceptable. trainings. We consolidate learning and results across the different Unacceptable because A MOBILEH.R.H. CROWN HEALTH TOOL FOR SKILLED implementation settings. most maternal and PRINCESS MARY OF Available for newborn deaths are DENMARK Produced by: Maternity Foundation is a Danish development organization that aimspreventable. We know BIRTHSince 2010, H.R.H.ATTENDANTSFor more information go to www.safedelivery.org what to do and small, Crown Princess Mary #safedeliveryapp #maternityfoundation @MaternityF And supported by: to reduce maternal and newborn mortality in low- and middle-incomecost-effective interven- of Denmark has been "tions are available. patron of Maternity countries by developing innovative maternal health solutions and Let’s end this tragedy.” Foundation. free for all implementing sustainable health programs. Specialists Dr. Stine Lund and Dr. Bjarke Lund Sørensen from Univer- implementing sity of Copenhagen and University of Southern Denmark have been responsible for all scientific testing.
The Safe Delivery App is based on international guidelines from WHO partners (the World Health Organization) as well as ALSO (Advanced Life Support The Safe Delivery App is freely available for download at the in Obestrics), FIGO (the International Federation of Gynecology and App Store and Google Play and will be rolled out in low- and Obstetrics), RCOG (the Royal College of Obstetricians and Gynae- middle-income countries in partnership with key implemen- cologists), and ACOG (the American Congress of Obstetricians and ting partners in each country, e.g. ministries of health and Gynecologists). non-governmental organizations. The Safe Delivery App is funded by MSD for Mothers, the Bill & Melinda The mHealth Competency Center - located at Maternity Gates Foundation and a number of non-disclosed partners. “That women risk life to Foundation - supports partners with localized adapta tions of the give life is a tragedy and App, technical support, our implementation toolbox and with The Safe Delivery App is developed by: unacceptable. trainings. We consolidate learning and results across the different Unacceptable because H.R.H. CROWN implementation settings. most maternal and PRINCESS MARY OF newborn deaths are DENMARK Produced by: preventable. We know Since 2010, H.R.H. For more information go to www.safedelivery.org what to do and small, Crown Princess Mary #safedeliveryapp #maternityfoundation @MaternityF And supported by: cost-effective interven- of Denmark has been "tions are available. patron of Maternity Let’s end this tragedy.” Foundation. PRE-CONGRESS WORKSHOPS Sunday June 10th, 2018
Pre-congress workshops I, at 10:00 – 13:00:
Laparoscopy training Organiser: Negin Jaafar, MD Max. number of participants: 24 1 Location: Torben With, the Clinic Building, Odense University Hospital
Reproductive Health in Low Income Countries. Collaborations with Nordic Countries. Examples from the field and lessons Learned. What describes the fruitful, sustainable collaboration? Organiser: Bjarke Lund Sørensen, MD, PhD Max. number of participants: 24 2 Location: Fr. Chr. Krebs, the Clinic Building, Odense University Hospital
Managing menopause Organisers: Pernille Ravn, MD, DMSc & Sven Skouby, Professor, MD, DMSc Max. number of participants: 24 16 3 Location: Aage Berntsen, the Clinic Building, Odense University Hospital
Perineal tears and sphincter ruptures – anatomy, diagnosis, theory, suturing, and follow-up handling Organisers: Karl Møller Bek, MD, PhD & Sara Kindberg, Midwife, PhD. Max. number of participants: 24 4 Location: Marie Krogh, the Clinic Building, Odense University Hospital
Hysteroscopy training; learn, practice and acquire skills! Organiser: Margit Dueholm, MD, PhD & Bente Bækholm Poulsen, MD Max. number of participants: 24 5 Location: To be determined, participants will be informed directly
Intrapartum ultrasound Organiser: Geske Bak, MD, Torbjørn Moe Eggebø, Professor Max. number of participants: 24 6 Location: Emil Aarestrup, the Clinic Building, Odense University Hospital
The workshops are allocated on a first come, first served basis. Price per workshop: ++ If you are signed up for the congress, the price is 350 DKK. ++ If you are not signed up for the congress, the price is 700 DKK.
The price is including sandwich and beverage Pre-congress workshops II, at 14:00 – 17:00:
Robotic surgery - where are we today? Organiser: Pernille Tine Jensen, MD, PhD Max. number of participants: 24 Location: The MDT Conference Room, 5th floor, Department of Obstetrics and Gynecology, 7 OUH Odense University Hospital
Laparoscopy training Organiser: Negin Jaafar, MD Max. number of participants: 24 8 Location: Torben With and the forecourt, the clinic building, Odense University Hospital
Simulation-based medical education in obstetrics Organisers: Jette Led Sørensen, MD, PhD, MEEd & Tim Draycott, Obstetrician, MD, MBBS, MRCOG Max. number of participants: 12 9 Location: Nielsine Nielsen, the Clinic Building, Odense University Hospital
Colposcopy. Underestimation or overtreatment - Is more always better? Organiser: Lone Kjeld Petersen, MD, DMSc, Berit Booth Bargum, MD, PhD-student, Gitte Ørtoft, MD DMSc Max. number of participants: 24 10 Location: Aage Berntsen, the Clinic Building, Odense University Hospital 17 Infections in obstetrics and gynaecology: The Vagina, “It gets no respect” (subtitle“Döderlein, Dukes and DNA”) Organisers: Ronnie Lamont, Professor & Per-Goran Larsson, Professor Max. number of participants: 24 11 Location: Marie Krogh, the Clinic Building, Odense University Hospital
Gynecological ultrasound: theory, practice and pitfalls Organisers: Abelone Sakse, MD, PhD, Eva Dreisler, MD, PhD & Dorthe Hartwell, MD, PhD Max. number of participants: 24 12 Location: Emil Aarestrup, the Clinic Building, Odense University Hospital
Telemedicine and home-– The future is here, but how to join? Obstetric home-monitoring as example Organiser: Claus Duedal Pedersen, Chief innovation consultant, Olav Bjørn Petersen, Consultant, telemedicine project manager, AUH Aarhus University Hospital Max. number of participants: 50 13 Location: Syddansk Sundhedsinnovation, Forskerparken 10 – building G, 5230 Odense M
Gynecological disorders in Adolescents Organiser: Kresten Rubeck Petersen, MD, DMSc Max. number of participants: 24 14 Location: Fr. Krebs, the Clinic Building, OUH Odense University Hospital
Guide to the location on the website: nfog2018.dk/program/pre-congress-workshops/ 18 Sunday June 10th - Wednesday June 13th PROGRAMME
19
Sunday June 10th 2018
10:00 – 13:00 Workshops (1-6)
13:00 – 14:00 Sandwich and beverage
14:00 – 17:00 Workshops (7-14)
16:00 – 20.00 Registration
19:30 Get Together Monday June 11th 2018
07:30 – Registration
09:00 – 10:00 Welcome and opening session Plenary Awards; Young scientist & AOGS prizes Chair: Bjarne Rønde Kristensen, Congress President Location: Store Sal
10:00 – 10:30 Coffee & exhibition
10:30-12:00: 1. Hysterectomy - new perspectives Chair: Axel Forman & Vibeke Lysdal PARALLEL Location: Store Sal SESSION 1 ++ Live surgery - hysterectomy Presenters: Martin Rudnicki & Torben Munk ++ Success factors for fast track surgery Presenter: Marit Lieng, Norway ++ Fast track surgery - the America perspective Presenter: Jon Einarsson, USA ++ Discussion
20 2. Pregnancy as a window to future health Chair: Christina Vinter & Niels Uldbjerg Location: Konservatoriesalen ++ Obstetrical syndromes and reflections on the impact on the future health of women and their children Presenter: David McIntyre, Australia ++ Preeclampsia and future cardiovascular risk Presenter: Ralf Dechend, Germany ++ Canadian experiences with maternal postpartum follow-up clinics after adverse pregnancy outcome Presenter: Graeme Smith, Canada 3. Free communications - Reproduction & Oncogynecology Chair: Antti Perheentupa & Pernille T. Jensen Location: Pro Musica salen
10:30 - 10:40: O32 - Human Papillomavirus in the semen and genital tract of normal fertile men Presenter: Jens Fedder 10:40 - 10:50: O31 - Flow cytometric software for determination of DNA fragmentation in sperm Presenter: Anne Sofie Rex
10:50 - 11:00 O34 - Risk of stillbirth in uncomplicated singleton term pregnancies following IVF/ISCI Presenter: Bjørn Bay
11:00 - 11:10: O33 - No relapse of breast cancer after IVF childbirth Presenter: Emma Rosenberg
11:10 - 11:20: O51 - Ovarian cancer characteristics and survival in a defined complete population Presenter: Arna Rut Emilsdóttir 20:00 Get Together
07:30 – Registration 11:20 - 11:30: O47 - Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - A comparative cohort study 09:00 – 10:00 Welcome and opening session Presenter: Mette Calundann Noer Plenary Awards; Young scientist & AOGS prizes Chair: Bjarne Rønde Kristensen, Congress President 11:30 - 11:40: O54 - Sentinel node mapping in women with endometrial cancer Location: Store Sal Presenter: Sara Sponholtz
10:00 – 10:30 Coffee & exhibition 11:40 - 11:50: O50 - Methylation can predict progression of cervical intraepithelial neoplasia grade 2 Presenter: Karolina Louvanto 10:30-12:00: 1. Hysterectomy - new perspectives Chair: Axel Forman & Vibeke Lysdal 11:50 - 12:00: O49 - HPV-test in triage of ASC-US / LSIL - The CIN3+ risk in 5-type HPV E6/E7 mRNA PARALLEL Location: Store Sal negative women Presenter: Finn Egil Skjeldestad SESSION 1 ++ Live surgery - hysterectomy Presenters: Martin Rudnicki & Torben Munk 12:00 – 13:00 Lunch & exhibition Lunch Symposia: Location: Store Sal ++ Success factors for fast track surgery Presenter: Marit Lieng, Norway 13:00 – 14:30 1. Ovarian cancer - future perspectives. Surgery or chemotherapy? ++ Fast track surgery - the America perspective Chair: Jan Blaakær & Stinne Holm Bergholdt Presenter: Jon Einarsson, USA PARALLEL Location: Store Sal SESSION 2 ++ Combined surgical and medical treatment of ovarian cancer - Hypertherm IntraPEritoneal ++ Discussion Chemotherapy (HIPEC) Presenter: Willemien van Driel, Netherlands 2. Pregnancy as a window to future health 21 Chair: Christina Vinter & Niels Uldbjerg ++ Laparoscopic treatment of recurrent ovarian cancer - Pressurized Intra Peritoneal Aerosol Location: Konservatoriesalen Chamotherapy (PIPAC) ++ Obstetrical syndromes and reflections on the impact on the future health of women and their children Presenter: Michael Bau Mortensen, Denmark Presenter: David McIntyre, Australia ++ New Landmarks in the treatment of recurrent ovarian cancer. Niraparib and other PARP inhibitors ++ Preeclampsia and future cardiovascular risk Presenter: Mansoor Mirza, Denmark Presenter: Ralf Dechend, Germany ++ Discussion in plenum ++ Canadian experiences with maternal postpartum follow-up clinics after adverse pregnancy outcome 2. Reproductive medicine - the oocyte Presenter: Graeme Smith, Canada Chair: Jens Fedder & Ulrik Schiøler Kesmodel 3. Free communications - Reproduction & Oncogynecology Location: Pro Musica salen Chair: Antti Perheentupa & Pernille T. Jensen ++ Oocyt donation - law in the nordic countries, practice and indications Location: Pro Musica salen Presenter: Ann Thurin Kjellberg, Sweden 10:30 - 10:40: O32 - Human Papillomavirus in the semen and genital tract of normal fertile men ++ Oocyt donation - fertility tourism and ethical aspects Presenter: Jens Fedder Presenter: Viveca Söderström-Anttila, Finland 10:40 - 10:50: O31 - Flow cytometric software for determination of DNA fragmentation in sperm ++ Cryo preservation of oocyts and ovarian tissue Presenter: Anne Sofie Rex Presenter: Erik Ernst, Denmark
10:50 - 11:00 O34 - Risk of stillbirth in uncomplicated singleton term pregnancies following IVF/ISCI Presenter: Bjørn Bay
11:00 - 11:10: O33 - No relapse of breast cancer after IVF childbirth Presenter: Emma Rosenberg
11:10 - 11:20: O51 - Ovarian cancer characteristics and survival in a defined complete population Presenter: Arna Rut Emilsdóttir 3. Free communications - Obstetrics & Global Health Chair: Lars. H. Pedersen & Mette H. Tanvig Location: Konservatoriesalen
13:00 - 13:10: O1 - A qualitative study on the challenges of providing maternity care in Greek refugee camps Presenter : Hannah Scott
13:10 - 13:20: O14 - Emotional violence during pregnancy and postpartum depression in Tanzania Presenter : Jane J. Rogathi
13:20 - 13:30: O4 - Intimate Partner Violence among Pregnant Women and Exclusive Breastfeeding Presenter: Frederikke Kjerulff Madsen
13:30 - 13:40: O22 - Sleeping problems in pregnancy Presenter : Linda Aukia
13:40 - 13:50: O2 - Guidelines’ effect on managing hypertensive disorders at Zanzibar’s main hospital Presenter : Nanna Maaløe
13:50 - 14:00: O18 - Maternal deaths from hypertensive disorders: lessons learnt Presenter : Lill Trine Nyfløt
14:00 - 14:10: O8 - Causes of stillbirth by gestational age: added value of postmortem examination Presenter: Maria Pekkola
14:10 - 14:20: O3 - Influence of postpartum depression on child growth: A cohort study. 22 Presenter : Christina Elise Holm-Larsen 14:20 - 14:30: O10 - Childbirth in Swedish women with vaginismus or localised provoked vulvodynia Presenter: Louise Möller
14:30 - 15:30 Coffee & exhibition
15:30-17:00 1. Vulva; perception and female genital cutting Chair: Pernille Ravn & Kamilla Kannegård PARALLEL Location: Pro Musica salen SESSION 3 ++ Selfperception of the vulva Presenter: Annemette Lykkebo, Denmark ++ Cutting of the labia - pro and con Presenter: Christina Damsted, Denmark ++ Effects of female genital cutting on physical health outcomes and how to prevent it Presenter: Rigmor C. Berg, Norway ++ Discussion in plenum
2. How do modulators and regulators of pregnancy determine infant health? Chair: Jan Stener Jørgensen & Niels Uldbjerg Location: Store Sal ++ Preterm delivery - genes and mechanisms Presenter: Bo Jacobsson, Sweden ++ To seed or not to seed – what is the evidence for vaginal seeding? Presenter: Tine D. Clausen, Denmark ++ Maternal exposure to endocrine disrupting chemicals and health in the offspring Presenter: Tina Kold Jensen, Denmark 3. Free communications - General gynecology & Global Health Chair: Marit Lieng & Vibeke Rasch Location: Konservatoriesalen
15:30 - 15:40: O5 - Mapping the lack of public initiative against female genital mutilation in Denmark Presenter : Vibeke Næser
15:40 - 15:50: O7 - Pelvic organ prolapse in Tanzania – prevalence and risk factors Presenter : Gileard Masenga
15:50 - 16:00: O6 - Mobile intervention to increase cervical screening attendance among Tanzanian women Presenter : Ditte Søndergaard Linde
16:00 - 16:10: O48 - High-grade lesions in relation to reproductive characteristics and HIV status Presenter : Patricia Swai
16:10 - 16:20: O52 - Performance of VIA, HC2 and CareHPV in detection of cervical pre cancerous lessons Presenter : Ditte Søndergaard Linde
16:20 - 16:30: O53 - Risk for CIN3+ in women with a negative cervical biopsy Presenter : Finn Egil Skjeldestad
16:30 - 16:40: O36 - Iatrogenic gynecologic fistula; results from a Norwegian national competence center Presenter : Jone Trovik 23 16:40 - 16:50: O46 - Pelvic floor muscle training and intravaginal electrical stimulation in women with spinal cord injury: A randomized clinical trial study Presenter : Marlene Elmelund
16:50 - 17:00: O40 - No association between native tissue vaginal vault suspension and risk of pelvic pain or sexual dysfunction. Presenter : Lisbeth Bonde
17:00 – 18:00 Poster Session 1 Chair: Marit Lieng, Ulrik Schiøler Kesmodel, Martin Rudnicki & Lene Sperling Location: Poster area and main entrance of Odeon Tuesday June 12th 2018
06:30 – 07:00 NFOG “Run for womens global health and rights”
08:30 - 09:00 The microbiome and women's reproductive health Plenary Chair: Jan Stener Jørgensen & Ronald Francis Lamont Location: Store Sal Presenter: Lars Engstrand, Sweden
09:00 - 09:00 Meet the editors – discussion in plenum Plenary Chair:Ulrik Schiøler Kesmodel Location: Store sal Debaters: Ganesh Archarya / Anja Pinborg / Sandy Goldbeck-Wood
09:45 - 10:30 Coffee & exhibition
10:30 - 12:00 1. Contraception/HRT update Chair: Kresten Rubeck Petersen & Oskari Heikinheimo PARALLEL Location: Store Sal SESSION 4 ++ Perimenopausal hormone replacement therapy – the present and the future Presenter: Ellen Løkkegård, Denmark ++ Future directions for optimal contraception in all ages 24 Presenter: Ingela Lindh, Sweden ++ Sexual transmitted infections (STIs) –in OB/GYN – whats´s new? Presenter: Jørgen Skov Jensen, Denmark 2. Delivery and pelvic floor disorders Chair: Ulla Darling Hansen Location: Meeting Room 107, 1st floor ++ Can we predict and prevent delivery-related pelvic floor disorders Presenter: Ian Milsom, Sweden ++ Pelvic floor disorders and mode of delivery Presenter: Åsa Leijonhufvud, Sweden ++ Long-term effects of vacuum extraction on pelvic floor function Presenter: Maria Gyhagen, Sweden 3. Women´s health in a global perspective Chair: Vibeke Rasch & Garnesh Acharya Location: Pro Musica salen ++ The widening inequity gap in women’s health Presenter: Albrecht Jahn, Germany ++ Precision Medicine Applied to Women´s Health in a Global Perceptive Presenter: Chiara Benedetto, Italy ++ Empowerment of women by Community-Based Health Education - cervical cancer prevention in Nepal Presenter: Sunila Shakya, Nepal ++ Gender inequality and intimate partner violence among pregnant women in Tanzania Presenter: Geofrey Shigalla, Tanzania 4. Free communications - Obstetrics & Fetal Medicine Chair: Lene Sperling & Hulda Hjartadóttir Location: Konservatoriesalen 06:30 – 07:00 NFOG “Run for womens global health and rights” 10:30 - 10:40: O28 - Pregnancy and early childhood outcomes of euploid pregnancies with a high 08:30 - 09:00 The microbiome and women's reproductive health risk in the first-trimester combined screening Plenary Chair: Jan Stener Jørgensen & Ronald Francis Lamont Presenter : Outi Äyräs Location: Store Sal 10:40 - 10:50: O30 - Validation of the SNP–Based NIPT in Twin Gestations for Zygosity-, Presenter: Lars Engstrand, Sweden Individual-Fetal-Gender–, and Aneuploidy-Determination Presenter : Samantha Leonard 09:00 - 09:00 Meet the editors – discussion in plenum Plenary Chair:Ulrik Schiøler Kesmodel 10:50 - 11:00: O26 - Management of suspected primary toxoplasma infection in pregnant women: Location: Store sal twenty years of experience of amniocentesis in a low-prevalence population Presenter : Gry Findal Debaters: Ganesh Archarya / Anja Pinborg / Sandy Goldbeck-Wood 11:00 - 11:10: O13 - Effect of maternal hypothyroidism and levothyroxine use during pregnancy on 09:45 - 10:30 Coffee & exhibition pregnancy and perinatal outcome 10:30 - 12:00 1. Contraception/HRT update Presenter : Suvi Turunen Chair: Kresten Rubeck Petersen & Oskari Heikinheimo 11:10 - 11:20: O15 - Fetal cardiac dysfunction at term gestation in type 1 diabetic pregnancies. PARALLEL Location: Store Sal Presenter : Lara Lehtoranta SESSION 4 ++ Perimenopausal hormone replacement therapy – the present and the future 11:20 - 11:30: O19 - Metformin treatment of pregnant women with polycystic ovary syndrome Presenter: Ellen Løkkegård, Denmark - a Nordic RCT ++ Future directions for optimal contraception in all ages Presenter : Tone Løvvik Presenter: Ingela Lindh, Sweden 11:30 - 11:40: O17 - Maternal allergy as an isolated risk factor for early-onset preeclampsia 25 ++ Sexual transmitted infections (STIs) –in OB/GYN – whats´s new? Presenter : Anne Kvie Sande Presenter: Jørgen Skov Jensen, Denmark 11:40 - 11:50: O27 - Outcome in monoamniotic twin pregnancies managed primarily by outpatient 2. Delivery and pelvic floor disorders care Chair: Ulla Darling Hansen Presenter : Caroline Madsen Location: Meeting Room 107, 1st floor 11:50 - 12:00: O29 - Umbilical vein volume blood flow and uterine artery Doppler indices. ++ Can we predict and prevent delivery-related pelvic floor disorders Presenter : Amarnath Bhide Presenter: Ian Milsom, Sweden 12:00 - 13:00 Lunch & exhibition ++ Pelvic floor disorders and mode of delivery Lunch Symposia I: Location: Store Sal Presenter: Åsa Leijonhufvud, Sweden Lunch Symposia II: Location: Pro Musica salen ++ Long-term effects of vacuum extraction on pelvic floor function 13:00 - 14:00 Poster Session 2 Presenter: Maria Gyhagen, Sweden Chair: Marit Lieng, Ulrik Schiøler Kesmodel, Mette H. Tanvig & Jan Blaakær 3. Women´s health in a global perspective Location: Poster area and main entrance of Odeon Chair: Vibeke Rasch & Garnesh Acharya 14:00 - 15:30 1. Presidents session: Location: Pro Musica salen Chair: Bjarne Rønde Kristensen, Karen Wøjdemann & Negin Jaafar ++ The widening inequity gap in women’s health PARALLEL Location: Store Sal Presenter: Albrecht Jahn, Germany SESSION 5 ++ ” Women’s rights to exist, to choose and to decide” ++ Precision Medicine Applied to Women´s Health in a Global Perceptive Presenter: Sara Omar, Author- human and women rights fighter, Denmark/Kurdistan Presenter: Chiara Benedetto, Italy ++ To be announced ++ Empowerment of women by Community-Based Health Education - cervical cancer prevention in Nepal Presenter: To be announced Presenter: Sunila Shakya, Nepal ++ Gender inequality and intimate partner violence among pregnant women in Tanzania Presenter: Geofrey Shigalla, Tanzania 2. Fetal medicine now and in the future Chair: Lene Sperling & Andreas Herbst Location:Pro Musica salen ++ The first and second trimester screening in a Nordic perspective. Where are we now? Presenter: Torbjørn Eggebø, Norway ++ The genetic perspectives and challenges in relation to Fetal Medicine Presenter: Ida Vogel, Denmark ++ How should we act when we determine brain sparing in the third trimester? Presenter: Basky Thilaganathan, United Kingdom ++ Discussion in plenum
3. Free communications - General gynecology Chair: Annika Strandell & Martin Rudnicki Location: Konservatoriesalen
14:00 - 14:10: O35 - Fertility outcome after cornual resection for interstitial pregnancies Presenter : Rune Svenningsen
14:10 - 14:20: O41 - Physical Activity after Outpatient Total Laparoscopic Hysterectomy: Results from a RCT. Presenter : Ulla Juul Christiansen
14:20 - 14:30: O37 - Investigating the loss of work productivity due to symptomatic leiomyoma Presenter : Helena Kopp Kallner
26 14:30 - 14:40: O40 - Treatment of abnormal uterine bleeding by endometrial ablation: comparison of treatment in two periods Presenter : Knut Hordnes
14:40 - 14:50: O38 - Lichen sclerosus and risk of cancer Presenter : Pia Halonen
14:50 - 15:00: O44 - The risk of breast cancer in women with endometriosis Presenter : Liisu Saavalainen
15:00 - 15:10: O43 - Reduction in teenage pregnancies – a cross-sectional multinational study Presenter : Ingela Lindh
15:10 - 15:20: O45 - The risk of psychiatric morbidity after teenage childbirth and induced abortion Presenter : Eerika Jalanko
15:20 - 15:30: O42 - Prescription patterns of COCs - do gynecologists comply with guidelines? Presenter : Finn Egil Skjeldestad
15:30 - 16:00 Coffee & exhibition 16:00 - 17:30 1. Medical education Chair: Jette Led Sørensen & Lise Brogaard PARALLEL Location: Pro Musica salen SESSION 6 ++ Introduction and trends in medical education Presenter: Jette Led Sørensen, Denmark ++ Obstetric simulation Presenter: Tim Draycott, United Kingdom ++ Inter professional simulation in obstetrics Presenter: Signe Egenberg, Norway ++ Assessment of skills in surgery Presenter: Jeanett Strandbygaard, Denmark ++ Simulation-based education in ultrasound Presenter: Martin Tolsgaard, Denmark ++ Discussion in plenum
2. Minimal invasive surgery (NSGE session) When love hurts Chair: Martin Rudnicki Location: Store Sal ++ New perspectives on endometriosis: Causes of pain and infertility Presenter: Robert Tailor, USA ++ Minimally-disruptive, stepwise management of symptomatic endometriosis Presenter: Paolo Vercellini, Italy 27 ++ Current management of infertility due to endometriosis Presenter: Nan Oldereid, Norway ++ Adverse outcome of pregnancy due to endometriosis Presenter: Päivi Härkki, Finland 3. Spontaneous preterm birth (SPBC session) Chair: Jan Stener Jørgensen & Nils-Halvdan Morken Location: Konservatoriesalen ++ Spontaneous preterm birth - an update Presenter: Ronald Francis Lamont, United Kingdom ++ Progesterone - pro et con Presenters: Zarko Alfirevic, United Kingdom / Andrew Shennan, United Kingdom ++ Cortocosteroids - pro et con Presenters: Hanns Helmer, Austria / Sarah Stock, Scotland 16:00 – 17:30 NFOG general assembly Location: The Meeting Room 107, 1st floor
19:30 Congress dinner Wednesday June 13th 2018
08:30 - 09:00 HPV vaccination - The Danish experience Plenary Chair: Jan Blaakær Location: Store Sal Presenter: Søren Brostrøm, Denmark
09:00 - 09:30 Management of early onset IUGR Plenary Chair: Jan Stener Jørgensen Location: Store Sal Presenter: Zarco Alfirevic, United Kingdom
09:30 – 10:00 Coffee & exhibition
10:00 - 11:30 1. Reproductive medicine - andrology Chair: Jens Fedder & Antti Perheentupa PARALLEL Location: Pro Musica salen SESSION 7 ++ Semen quality and future health risks Presenter: Anders Juul, Denmark ++ Obesity, sperm fatty acids and semen quality Presenter: Trine Haugen, Norway ++ Treatment of men with non-obstructive azoospermi – new breakthroughs in an ethical perspective 28 Presenter: Jens Fedder, Denmark 2. Obesity - NOCOGO session Chair: Christina Vinter & Dorte Møller Jensen Location: Store Sal ++ Management of overweight and obesity in PCOS Presenter: Eszter Vanky, Norway ++ Obesity epidemic - perspectives from India Presenter: Ranjan Yajnik, India ++ Obesity and fertility Presenter: Katrine Birch Petersen, Denmark ++ Discussion in plenum
3. Free communications - Obstetrics Chair: Hulda Hjártadóttir & Peter Damm Location: Konservatoriesalen
10:00 - 10:10: O9 - Changes in labor outcome after implementing judicious use of oxytocin Presenter: Fride E. Austad
10:10 - 10:20: O11 - Discontinuation of intravenous oxytocin in the active phase of induced labour: Cochrane review Presenter: Sidsel Boie
10:20 - 10:30: O48 - Fetal rotation during vacuum extractions; a prospective cohort study Presenter: Birgitte Heiberg Kahrs 08:30 - 09:00 HPV vaccination - The Danish experience 10:30 - 10:40: O16 - Lateral episiotomy in vacuum-assisted delivery (EVA) - a randomized trial Plenary Chair: Jan Blaakær Presenter: Sophia Brismar Wendel Location: Store Sal 10:40 - 10:50: O23 - Sonographic prediction of outcome of vacuum deliveries: a prospective, Presenter: Søren Brostrøm, Denmark multicenter cohort study Presenter: Birgitte Heiberg Kahrs 09:00 - 09:30 Management of early onset IUGR 10:50 - 11:00: O21 - Risk factors for obstetric anal sphincter injury at first and second delivery Plenary Chair: Jan Stener Jørgensen Presenter: Ida Nilsson Location: Store Sal 11:00 - 11:10: O52 - Severe fatigue after postpartum haemorrhage treated with intravenous iron Presenter: Zarco Alfirevic, United Kingdom Presenter: Charlotte Holm 09:30 – 10:00 Coffee & exhibition 11:10 - 11:20: O24 - Team up to save lives: video analysis of teams’ management of postpartum 10:00 - 11:30 1. Reproductive medicine - andrology hemorrhage. Presenter: Lise Brogaard Chair: Jens Fedder & Antti Perheentupa PARALLEL Location: Pro Musica salen 11:20 - 11:30: O25 - Weight loss reduces recurrence of gestational diabetes mellitus Presenter: Linn Marie Sorbye SESSION 7 ++ Semen quality and future health risks Presenter: Anders Juul, Denmark 11:30 - 12:15 Lunch & exhibition ++ Obesity, sperm fatty acids and semen quality 12:15 - 13:45 1. Abortion: Law, access and prevention Presenter: Trine Haugen, Norway Chair: Pernille Ravn ++ Treatment of men with non-obstructive azoospermi – new breakthroughs in an ethical perspective PARALLEL Location: Konservatoriesalen Presenter: Jens Fedder, Denmark 29 SESSION 8 ++ Global abortion laws and access to safe abortion 2. Obesity - NOCOGO session Presenter: Vibeke Rasch, Denmark Chair: Christina Vinter & Dorte Møller Jensen ++ Improving access to safe abortion - 25 years of mifepristone Location: Store Sal Presenter: Kristina Gemzell-Danielsson, Sweden ++ Management of overweight and obesity in PCOS ++ 2nd trimester abortion in Scandinavia: laws, practice and unmet need Presenter: Eszter Vanky, Norway Presenter: Øjvind Lidegaard, Denmark ++ Obesity epidemic - perspectives from India ++ Preventing subsequent abortion Presenter: Ranjan Yajnik, India Presenter: Oskari Heikinheimo, Finland ++ Obesity and fertility 2. Preeclampsia Presenter: Katrine Birch Petersen, Denmark Chair: Ralf Dechend, Britta Frederiksen-Møller & Andreas Herbst ++ Discussion in plenum Location: Pro Musica salen 3. Free communications - Obstetrics ++ Preeclampsia: a placenta disorder? Chair: Hulda Hjártadóttir & Peter Damm Presenter: Chris Redman, United Kingdom Location: Konservatoriesalen ++ Preeclampsia: a cardiac disorder? 10:00 - 10:10: O9 - Changes in labor outcome after implementing judicious use of oxytocin Presenter: Basky Thilangatam, United Kingdom Presenter: Fride E. Austad ++ Discussion in plenum 10:10 - 10:20: O11 - Discontinuation of intravenous oxytocin in the active phase of induced labour: ++ Pre-eclampsia biomarkers: more than you think Cochrane review Presenters: Anne Cathrine Staff, Norway Presenter: Sidsel Boie ++ Discussion in plenum 10:20 - 10:30: O48 - Fetal rotation during vacuum extractions; a prospective cohort study Presenter: Birgitte Heiberg Kahrs 3. NFOG Thesis session Chair: Annika Strandell, Antti Perheetupa, Hulda Hjartadóttir, Marit Lieng & Lars H. Pedersen Location: Store Sal ++ Antenatal lifestyle intervention for limitation of gestational weight gain – the Norwegian fit for delivery trial Presenter: Linda Reme Sagedal, Norway ++ Recurrent Pregnancy Loss – a family affair | Studies of genetics, epidemiology and evolution Presenter: Astrid Marie Kolte, Denmark ++ Planned home births in Iceland: Premise, outcome and influential factors Presenter: Berglind Hálfdánsdóttir, Iceland ++ Fetal heart and hemodynamics in diabetic pregnancy - Fetal cardiac and placental function in a rat model of maternal hyperglycemia and human type 1 diabetic pregnancies Presenter: Lara Lehtoranta, Finland ++ Cardiac disease in pregnancy and consequences for reproductive outcomes, comorbidity and survival Presenter: Kristina Kernell, Sweden 13:45 – 14:00 Coffee & exhibition
14:00 - 15:00 Hot topics Plenary Location: Store Sal Chair: Ulrik Schiøler Kesmodel & Jan Stener Jørgensen ++ A day without randomisation is a day without progress Presenter: Ben Mol, Australia 30 Chair: Pernille Ravn ++ The utility of genetic testing - now and in the future Presenter: Henriette Roed Nielsen, Denmark 15:00 - 15:30 Prizes and closing Plenary Location: Store Sal Chair: Bjarne Rønde Kristensen 31 PROGRAMME AT A GLANCE
Time Monday June 11th 2018 09:00 – 10:00 Welcome and opening session Plenary Awards; Young scientist & AOGS prizes Location: Store Sal 10:00 – 10:30 Coffee & exhibition 10:30 – 12:00 Hysterectomy - new perspectives Pregnancy as a window to future Free communications Parallel session 1 Location: Store Sal health Reproduction & Oncogynecology Location: Konservatoriesalen Location: Pro Musica salen 12:00 – 13:00 Lunch & exhibition Lunch Symposia: Location: Store Sal 13:00 – 14:30 Ovarian cancer - future perspec- Reproductive Medicine - the oocyte Free communications Parallel session 2 tives. Surgery or chemothe-rapy? Location: Pro Musica salen Obstetrics & Global Health Location: Store Sal Location: Konservatoriesalen 14:30 – 15:30 Coffee & exhibition 15:30 – 17:00 Vulva; perception and female genital How do modulators and regulators Free communications Parallel session 3 cutting of pregnancy determine infant General gynaecology & Global Health Location: Pro Musica salen health? Location: Konservatoriesalen Location: Store Sal 17:00 – 18:00 Poster Session 1 Location: Poster area and main entrance of Odeon 32
Time Tuesday June 12th 2018 08:30 – 09:45 The microbiome and women’s reproductive health Plenary Location: Store Sal Meet the editors – discussion in plenum Location: Store Sal 09:45 – 10:30 Coffee & exhibition 10:30 - 12:00 Contraception/HRT update Delivery and pelvic floor Women´s health in a Free communications Parallel session 4 Location: Store Sal disorders global perspective Obstetrics & Fetal Medicine Location: Meeting Room Location: Pro Musica salen Location: Konservatorie- 107, 1st floor salen 12:00 – 13:00 Lunch & exhibition Lunch Symposia I: Location: Store Sal Lunch Symposia II: Location: Pro Musica salen 13:00 - 14:00 Poster Session 2 Location: Poster area and main entrance of Odeon 14:00 - 15:30 Presidents session: Fetal medicine now and in Free communications General gynecology Parallel session 5 Location: Store Sal the future Location: Konservatoriesalen Location: Pro Musica salen 15:30 – 16: 00 Coffee & exhibition 16:00 - 17:30 Medical education Minimal invasive surgery Spontaneous preterm birth (SPBC session) Parallel session 6 Location: Pro Musica salen (NSGE session) When love Location: Konservatoriesalen hurts Location: Store Sal 16.00 – 17:30 NFOG general assembly Location: The Meeting Room 107, 1st floor 19:30 Congress Dinner
Time Wednesday June 13th 2018 08:30 - 09:30 HPV vaccination - The Danish experience Plenary Location: Store Sal
Management of early onset IUGR 33 Location: Store Sal 09:30 – 10:00 Coffee & exhibition 10:00 - 11:30 Reproductive medicine Obesity - NOCOGO session Free communications Parallel session 7 - andrology Location: Store Sal Obstetrics Location: Pro Musica salen Location: Konservatoriesalen 11:30 – 12:15 Lunch & exhibition 12:15 - 13:45 Abortion: Law, access and preven- Preeclampsia NFOG Thesis session Parallel session 8 tion Location: Pro Musica salen Location: Store Sal Location: Konservatoriesalen 13:45 – 14:00 Coffee & exhibition 14:00 - 15:00 Hot topics Plenary Location: Store Sal 15:00 – 15:30 Prizes and closing Location: Store Sal POSTERS Global Health
P1 Effects of criterion-based audit on management of prolonged labour Rasch Vibeke P2 Gestational age determination by last menstrual-period and ultrasound in Tanzania Nielsen Pernille Nathalie P3 International accreditation in ObGyn by commercial organisations does not comply Jacquemyn Yves with the actual medical ethic framework and should be abandoned P4 Long-term cardiometabolic effects of pre-pregnancy lifestyle interventions in obese Wekker Vincent women P5 Manual vacuum aspiration in the treatment of incomplete abortions in Malawi Odland Maria Lisa P6 MomIT: An innovative ICT-based intervention to maternal weight loss Skjøth Mette Maria P7 Pessaries in the management of stress urinary incontinence in Tanzania Shayo Benjamin P8 Prevention of birth-related perineal trauma and anal and urinary incontinence: results Mantzius Julie from a criterion-based audit at a referral hospital in Tanzania P9 Urinary-incontinence and delivery circumstances in Tanzania - a population-based study Masenga Gileard
34 Obstetrics
P10 A birth plan clinic reduced unnecessary cesarean sections without compromising Alvestad Melissa women’s birth experience P11 Abnormal cervical cytology is associated with preterm delivery Jar-Allah Tagrid P12 Alternative medicine and intake of fish-oil supplements is common among Danish, Volqvartz Tabia pregnant women P13 Association between mode of delivery and postpartum urinary tract infection Gundersen Tina Djernis P15 Behaviour and development screening in children at 7 to 10 years of age born after low Romero Stefhanie or mid pelvic vacuum-assisted delivery P16 Breastfeeding and long-term metabolic health: consequence or reverse causality? Velle-Forbord Veronica P17 Caesarean scar thickness in non-pregnant women as a risk factor for uterine rupture Risager Johanne P18 Carbetocin or oxytocin for prevention and management of postpartum hemorrhage? Brun Pedersen Camilla P20 Causes and predictors of postpartum blood loss: a cohort study Edwards Hellen P21 Cesarean delivery and antibiotics in early childhood do not cause autism Axelsson Paul B. P22 Cesarean section rate and complications at Hospital of Southern Jutland compared Nørskov Cathrine Lautrup with Danish cesarean rate and complications over time P23 Changes in drinking patterns, attitudes towards and knowledge about alcohol con- Urbute Aivara sumption during pregnancy in a population of pregnant Danish women P24 Do elite athletes experience more difficult birth than untrained? Geirsson Reynir Tómas P25 Fibre intake and lifestyle characteristics in relation to constipation and heartburn in Uotila Jukka pregnancy and pregnancy outcome – a questionnaire- based study P26 First trimester biochemical markers for early development of preeclampsia Pedersen Berit Woetmann P27 Gestational diabetes is associated with an aberrant salivary microbiota composition Crusell Mie K. W. P28 Group B streptococci cultured in urine during pregnancy associated with preterm Khalil Mohammed delivery: a selection problem? P29 Heterogeneity of gestational diabetes (GDM) and long-term risk of diabetes and meta- Huvinen Emilia bolic syndrome – findings from the RADIEL study follow-up P30 High use of ginger and licorice among Danish pregnant women during the first trimes- Volqvartz Tabia ter P31 Impact of income and traditional risk factors on gestational diabetes Rönö Kristiina P32 Incidence of postoperative infections after cesarean delivery in Denmark Winther Azalie P33 Increased induction of labor rate in obese, results in an increase of operative deliveries? Bonnichsen Maja Lecic P34 Increasing the incidence of vaginal delivery in nulliparous women. Rasmussen Ole Bredahl P35 Infant outcome after complete uterine rupture Al-Zirqi Iqbal P36 Intrapartum PCR assay versus antepartum culture for assessment of vaginal carriage Khalil Mohammed of group B streptococci in a Danish cohort at birth P37 Intrapartum ultrasound - a learning study Bertelsen Christine Buus P38 Intrauterine metformin exposure and metabolic health at 8-years of age Hanem Liv Guro Engen P39 Intravenous versus oral iron treatment in pregnancy: a study protocol Hansen Rebecka P40 Is time of quickening affected by maternal BMI, abdominal wall thickness and placen- Høltzermann Mette tal site? A prospective study. 35 P41 Keep it down: noise affects our performance Jensen Kristiane Roed P42 Labour in sensory delivery rooms reduce risk of obstetrical interventions. Wrønding Tine P43 Long-term cognition and behaviour when born early-term – a systematic review Nielsen Trine Muhs P44 Maternal outcome after complete uterine rupture Al-Zirqi Iqbal P45 Maternal outcome in pregnancies after a complete uterine rupture Thisted, MD Dorthe Louise Ahrenkiel P46 Misodel® or Angusta® for induction of labour? Roneklindt Axelina P48 Neuroticism is associated with higher antenatal care utilization in obstetric low-risk Axfors Cathrine women P49 Neuroticism is not associated with the risk of perinatal outcomes Axfors Cathrine P50 Number of colony forming units in urine at 35-37 weeks’ gestation as predictor of the Khalil Mohammed vaginal load of Group B Streptococci at birth P51 Outcome in high-risk pregnancies, managed by telemedicine home/self monitoring Petersen Olav Bjørn P52 Outcome in second pregnancy after HELLP syndrome in first Morken Nils-Halvdan P53 Outpatient induction of labour with low-dose misoprostol – a Danish descriptive cohort Bendix Jane M. study 2015-17 P54 Overweight, obesity and hyperandrogenism are associated with gestational diabetes Morin-Papu- Laure mellitus. nen P55 Pancytopenia in pregnancy: A Case Report Singh Manpreet P56 Perinatal outcomes in pregnancies of women with type 1 diabetes Gundersen Tina Djernis P57 Posterior Reversible Encephalopathy Syndrome in pregnancy - two case reports. Amirian Ilda P58 Prediction of severe complications in nulliparous women at term Nielsen Anna Pors P59 Predictors of prolonged intensive care unit treatment in severe pre-eclampsia Seikku Laura P60 Prenatal alcohol exposure and risk of Attention-Deficit-Hyperactivity-Disorder (ADHD) Weile Louise Katrine in the offspring: a prospective cohort study. Kjær P61 Prenatal exposures and risk for development of PCOS in the offspring Valgeirsdottir Heiddis P62 Prevalence and treatment of GBS: risk factors versus intrapartum screening Johansen Nanna Roed P64 Results after 8 months of implementing intrapartum antibiotic prophylaxis based on Terp Helene intrapartum GenomEra® PCR assay for group B streptococci P65 Risk evaluation during prenatal care Oddgeirsdóttir Hanna Lilja P66 Risk factors for preterm delivery among early onset cancer survivors Melin Johanna P67 Risk-based screening combined with a PCR-based test for group B streptococci Khalil Mohammed diminishes the use of antibiotics in laboring women P69 Self-detection of preeclampsia by automatic image processing of smartphone videos Jørgensen Jan Stener P70 Severe spastic cerebral palsy declined at term in Denmark 1999-2007 Langhoff-Roos Jens P72 Simulation training in intra-partum assessment of fetal head improves accuracy Iversen Johanne Kolvik P73 Spontaneous pneumomediastinum and subcutaneous emphysema postpartum in Kamstrup Lærke primipara Moser P74 Study design in obstetrics – a methodological challenge. Incidence of relevant obstetric Hoegh Stinne events and tentative sample size calculations P75 The buddy study - a peer support programme after adverse events Schrøder Katja 36 P76 The Childbirth Experience Questionnaire (CEQ) - validation of its use in Denmark Boie Sidsel P77 The effect of light versus strict activity restriction in threatened preterm deliveries – a Bendix Jane M. randomised controlled pilotstudy; The ELISTAR study P78 The effect of parity on risk of complications in women with epilepsy: a population Danielsson Kim based cohort study P79 The impact of tight antihypertensive treatment of true hypertension with white coat Vestgaard Marianne hypertension untreated in pregnant women with preexisting diabetes P80 The macronutrient preload method in gestational diabetes (GDM) - study of Preload® Rull Kristiina Balance usability and compliance. P81 The role of decidual Nrf2-expression in preeclampsia and fetal growth restriction Mundal Siv Boon P82 Time interval from elective cesarean section to severe complications Kruse Anne Raabjerg P83 Urinary plasminogen excretion may contribute to preeclampsia pathophysiology Nielsen Lise Hald Fetal Medicine
P84 Wound infection, dehiscence and risk of early secondary reconstruction following Barbosa Malou obstetric anal sphincter injury (OASIS) P85 A Scandinavian Cooperation: Incidence, prenatal detection rate and pregnancy out- Bodin Charlotte come of spina bifida in Denmark compared to Sweden Rosenkrantz P86 Birth weight variants are associated with variable fetal intrauterine growth from 20 Engelbrechtsen Line weeks of gestation. P87 Blood pressure in pregnancy as independent predictor for child health Birukov Anna P90 Evaluation of fetal cardiac function by electronic spatiotemporal image correlation Kolding Line (eSTIC) P91 Fetal heart rate variability with hypoxaemia Bhide Amarnath P92 Impaired RAAS, sodium balance in pregnancy and offspring cardiometabolic health Birukov Anna P93 Inadvertent Foetal Exposure to Methylene Blue in the First Trimester Donaldson Callum John P94 Metformin exposure during pregnancy alters the fetal venous liver circulation Kessler Jørg P95 Non-invasive fetal electrocardiography (fECG) in gestational week 32. Zizzo Anne Rahbek P96 Reference values for pH in umbilical cord arterial and venous blood and Apgar score Zaigham Mehreen from 34 to 42+ gestational weeks.
Reproduction 37
P98 Changes in human chorionic gonadotropin (hCG) as a predictor for live birth among Landersø Selma Kløve women with recurrent pregnancy loss (RPL) P99 Chronic endometritis in women with recurrent pregnancy loss Andersen Lærke Heidam Juul P100 Does coffee consumption impact on a successful fertility treatment? Lyngsø Julie P101 Gestational variation in the maternal serum cytokine profile during first half of preg- Stokkeland Live Marie T. nancy P102 Impact of uterine fibroids on fertility Karlsen Kamilla Kannegård P103 No effect of endometrial scratching before second IVF Maksimovic Milica P104 Ovulation Induction with Clomiphene Citrate and its Outcomes Hassan Serry Mohammad -Yaseen P105 Proportion of thyroid disorders among women referred for fertility treatment. Knudsen Ulla Breth P106 Risk of miscarriage in women conceiving after medically assisted reproduction (MAR) Riishede Iben with an ultrasound verified live pregnancy at gestational week 7 P107 Size matters – Placement of differently sized levonorgestrel intrauterine systems Hildingsson Inger P108 Testicular damages after testicular sperm retrieval evaluated histologically in a ram Fedder Jens model P109 Violence during pregnancy and maternal health, birth-outcomes in Vietnam Rasch Vibeke P110 What do fifteen-year-old pupils know about contraception? Hagemann Cecilie Therese General Gynecology
P111 3-dimensional versus conventional laparoscopy for hysterectomy: a randomized Hoffmann Elise clinical trial P112 Chronic vulvar pain among gynecological outpatients Teigen Per Kristen P113 CO2 laser for vaginal atrophy: Efficacy and side effects Hansen Rebecka P114 Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and Iversen Maja Lundegaard hysterectomy during the following 9-14 years. P115 Effects of a structured basic course on learning colposcopy Forsell Sabrina P116 Enterobicus Vermicularis in a 14-year-old non-sexually active female Hassan Mohammad-Yaseen Serry P117 Gynecological alarm symptoms: Lifestyle, socioeconomic status and contact to GP/ Balasubra- Kirubakaran gynecologist maniam P118 Hysteroscopic Mechanical Tissue Removal for treatment of intrauterine pathology in Botházi Attila outpatient setting: An observational study P119 Medical treatment of rectal endometriosis: symptoms and quality of life Egekvist Anne Gisselmann P120 Myocardial Infarction in Women with Polycystic Ovary Syndrome Rasmussen Anne Mette Odgaard P121 Nausea and vomiting of pregnancy: increased risk with affected relatives Laitinen Linda P123 Open Surgical Experience amongst Gynaecologists in the Scandinavian Countries Thinggaard Ebbe P124 Oral contraceptives for the treatment of primary dysmenorrhea. An updated Cochrane Schroll Jeppe 38 review P125 Ovarian lesion developing during and disappearing after 12-week lipristalacetate treat- Eriksson Olle ment. P126 Predicting low compliance to follow-up and IUD insertions after first trimester medical Pohjoranta Elina termination of pregnancy P127 Radiofrequency Ablation for Uterine Myomas: Long-term Clinical Outcomes and Rein- Iversen Helene terventions P128 Reducing the examination time and optimising a gynaecological examination with a Edelstam Greta new concept of a pelvic examination chair P129 Safe in-bag laparoscopic morcelation of myomas and large uteri Poulsen Bente Bækholm P130 Surgical treatment of endometriosis; a 5-years hospital cohort Trovik Jone P131 The First 200 patients in the Finnish sexual assault referral center – demographics Korjamo Riina and clinical findings P132 The gynecological patient’s attitudes towards the pelvic examination Damsgaard Katia Højsager P133 The role of office hysteroscopy with the vaginoscopic approach in women with an intact Wang Chin-Jung hymen P134 Two incidents of decidual cast as a side effect of hormone therapy - a case report Terp Helene P135 Ultrasound-guided radiofrequency ablation of uterine fibroids: short-term evaluation. Iversen Helene P136 Ureter lesions due to benign gynaecologic surgery; a 10-year hospital cohort Trovik Jone P137 Using virtual-reality simulation to ensure basic competence in hysteroscopy Savran Mona M. P138 Uterine fibroid incidence among Finnish women: an MRI screening study Lommi Markus P139 Validity of pre-operative self-reported weight in gynecological patients Naver Klara P140 Women with premenstrual dysphoria show right-sided dominance of frontal blood- Eriksson Olle flow. Urogynecology
P141 A Danish national population-based cohort study of midurethral slings, 2007-2011 Hansen Margrethe P142 Excluding vaginal birth - what would the demand for incontinence prolapse surgery Larsudd Jennie be? -Kåverud P143 First-line treatment of pelvic organ prolapse Glavind Karin P144 Long-term goal achievement after a tension-free vaginal tape operation. Glavind Karin P145 Long-term outcome after late repair of the anal sphincter secondary to obstetric Barbosa Malou trauma. P146 Mid-Urethral Sling Complications Continue to Occur 16 Years after Operation Tulokas Sari P147 Obstetric perineal wound infection and dehiscence: a prospective cohort study. Gommesen Ditte P148 Pelvic organ prolapse and other urogynecologic issues in women with spinal cord Elmelund Marlene injury P149 Pelvic organ prolapse surgery after vault suspension during hysterectomy Bonde Lisbeth – An observational study P150 Rate of recurrent apical prolapse after high uterosacral ligament suspension. Pedersen Katrine Dahl P151 Risk of unanticipated abnormal pathology at the time of and after uterine sparring Kjaergaard Niels pelvic organ prolapse (POP) surgery. P152 Tension-free vaginal tape – clinical outcomes and risk factors for recurrence Holdø Bjørn P153 The performance of the question “vaginal bulging” in nulliparous women Al-Mukhtar Jwan Othman P154 Treatment of urovaginal fistula by catheter drainage; a national competence- Trovik Jone 39 centre-cohort P155 Vaginal pessaries in the management of symptomatic pelvic organ prolapse in rural Shayo Benjamin Kilimanjaro, Tanzania: a pre-post interventional study Gynecological Oncology
P156 Burden of HPV-caused cancers in Denmark and the potential effect of HPV-vaccination Skorstengaard Malene P157 Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active Kalliala Ilkka surveillance - a systematic review and meta-analysis P158 Costs and consequences of introducing robotic surgery for women with gynecological Korsholm Malene cancer P159 High risk Human Papilloma virus in Tanzania-risk factors and type distribution Swai Patricia P160 HPV prevalence and HPV-related dysplasia in elderly women Hermansson Ruth P161 Impact of HLA-G on the outcome of genital and oral HPV infections in women Jaakola Anna P162 Improved survival for Danish women with advanced epithelial ovarian cancer treated in Fagö-Olsen Carsten Lindberg gynecological-oncological tertiary centers. P163 Nationwide introduction of robotic surgery for endometrial cancer reduces complications Jørgensen Siv Lykke P164 Risk factors of epithelial ovarian carcinomas among women with endometriosis: Thomsen Line Holdgaard a systematic review P165 Risk of endometrial cancer in women with endometrial hyperplasia Faurby Maarup Clara P166 The best are the worst: Computer adaptive testing of physical health after robotic Jørgensen Siv Lykke cancer surgery. P167 Uterine endometrioid adenocarcinoma with a co-existing non-gestational choriocarcinoma Neumann Gudrun
40 Other
P168 A national needs assessment to define curricular content for simulation-based train- Led Jette ing in gynecology and obstetrics Sørensen P169 Attitude toward emergency contraceptive pill and intention to use condoms in Korean Kim Hae Won male university students P170 Claims for compensation after gynecological treatment in Norway Ravlo Merethe P171 Conception and delivery-plan for Nordic electronic textbook of gynecology & obstetrics Uldbjerg Niels P172 Different stress responses by healthcare professionals during simulated medical Sørensen Jette Led emergencies. P173 Early detection of substance use in pregnancy Rausgaard Nete Lundager Klokker P174 Effect of oxidative stress on sperm cells investigated by label-free Quantitative Phase Popova Daria Microscopy P175 Evidence of no association between HPV and breast cancer. Simonsen Sara Bønløkke P176 Language Skills and Level of Experience among Arabic-Speaking Healthcare Inter- Khalil Mohammed preters in Denmark; an Explorative Study P177 Simulate anywhere - Design of simulation-based medical education and advantages Sørensen Jette Led and disadvantages of in situ simulation versus off-site simulation P178 Simulation in obstetrics – a survey of practice in Denmark Sørensen Jette Led SPEAKER INDEX
June 11th 2018 June 12th 2018 June 13th 2018
A Aukia, Linda A Acharya, Ganesh A Alfirevic, Zarco B Bay, Bjørn Alferevic, Zarko Austad, Fride E. Berg, Rigmor C. Äyräs, Outi B Boie, Sidsel Bonde, Lisbeth B Benedetto, Chiara Brogaard, Lise C Clausen, Tine Dalsgaard Bhide, Amarnath Brostrøm, Søren D Damsted, Christina C Christiansen, Ulla Juul F Fedder, Jens Dechend, Ralf D Draycott, Tim G Gemzell-Danielsson, Kristina E Einarsson, Jon E Egenberg, Signe H Hálfdánsdóttir, Berglind Elmelund, Marlene Eggebø, Torbjørn Moe Haugen, Trine Emilsdóttir, Arna Rut Engstrand, Lars Heikinheimo, Oskari Ernst, Erik F Findal, Gry Holm, Charlotte F Fedder, Jens G Goldbeck-Wood, Sandy J Juul, Anders H Holm-Larsen, Christina Elise Gyhagen, Maria K Kahrs, Birgitte Heiberg J Jacobsson, Bo H Halonen, Pia Kernell, Kristina Jensen, Tina Kold Härkki, Päivi Kolte, Astrid Marie K Kjellberg, Ann Thurin Helmer, Hanns L Lehtoranta, Lara L Linde, Ditte Søndergaard Hordnes, Knut Lidegaard, Øjvind Lieng, Marit J Jahn, Albrecht M Mol, Ben Louvanto, Karolina Jalanko, Eerika N Nielsen, Henriette Roed Lykkebo, Annemette Jensen, Jørgen Skov Nilsson, Ida 41 M Maaløe, Nanna K Kallner, Helena Kopp P Petersen, Kathrine Birch Madsen, Frederikke Kjerulff L Lamont, Ronald Francis R Rasch, Vibeke Masenga, Gileard Leijonhufvud, Åsa Redman, Chris McIntyre, David Lehtoranta, Lara S Sagedal, Linda Reme Mirza, Mansoor Leonard, Samantha Staff, Anne Cathrine Mortensen, Michael Bau Lindh, Ingela Sorbye, Linn Marie Munk, Torben Løkkegaard, Ellen T Thilangatam, Baskaran Möller, Louise Løvvik, Tone V Vanky, Eszter N Noer, Mette Calundann M Madsen, Caroline W Wendel, Sophia Brismar Nyfløt, Lill Trine Milsom, Ian Y Yajnik, Chittaranjan Næser, Vibeke O Oldereid, Nan P Pekkola, Maria Omar, Sara R Rex, Anne Sofie P Pinborg, Anja Rogathi, Jane J. S Saavalainen, Liisu Rosenberg, Emma Sande, Anne Kvie Rudnicki, Martin Shakya, Sunila S Scott, Hannah Shennan, Andy Skjeldestad, Finn Egil Shigalla, Geofrey Smith, Graeme Skjeldestad, Finn Egil Sponholtz, Sara Stock, Sarah Swai, Patricia Strandbygaard, Jeanett Söderström-Anttila, Viveca Svenningsen, Rune T Trovik, Jone Sørensen, Jette Led V van Driel, Willemien T Tailor, Robert Thilaganathan, Baskaran Tolsgaard, Martin Turunen, Suvi V Vercellini, Paolo Vogel, Ida INSTRUCTIONS FOR ORAL AND POSTER PRESENTERS Oral presentations The free oral presentation time will be maximum 7 minutes and 2 minutes for questions and discussion per speaker. Please bring your presentation on a USB stick to the Speaker PREP room the day before or no later than 2 hours before your pres- entation. There will be awards for the 3 best oral presentations. Presenters not adhering to the above time limit will not be eligible for an award. We kindly ask you to follow the instructions to ensure a successful and smooth progress of the timetable. In each auditorium there is a laptop available (Windows or Apple) which you are kindly requested to use. Please hand in your presentation in the Speakers PREP room: Room number 108 at the first floor in Odeon. Please bring your presentation on a USB stick saved in a version compatible with PowerPoint version 10 and please make sure the file is with your full name on! The presentations will be at widescreen format 16x9. Professional technicians will help you to transfer your presentation on the provided computers. In order to avoid queues and delays you must contact the technicians in the Speakers PREP room preferably the day before your presentation or in the morning no later than two hours before your presentation. 42 The technicians will be present on June 10th 2018 at 18:00 to 20:00 to assist speakers for Monday morning as well as during all days of the congress. If you are going to make a Prezi presentation we would like to know in advance, so send us an email. If you prefer to use your own laptop for special reasons you should bring your own adaptor as well. In case of doubt, contact a local assistant.
Poster presentations
The posters will be on display throughout the meeting (Monday-Wednesday) and should be ready for viewing no later than Monday at 10.00 o’clock. You are expected to be present at your poster on Monday 11th between 17.00-18.00 and on Tuesday 12th between 13.00-14.00.
The size of the poster should be with maximum sizes of: 95 cm width x 160 cm height.
Please prepare 1-3 Power Point -slides summarizing your poster for a possible oral poster presentation to be organized ei- ther on Monday 11th (17.00-18.00) or Tuesday 12th (13.00-14.00). The selected poster presenters will be notified by the NFOG Scientific Committee during Monday and Tuesday via the NFOG App and as a notification on the poster.
The brief oral presentation of selected posters should last no more than 2 minutes, leaving 2 minutes for questions and discussion. There will be awards for the 3 best oral poster presentations. Presenters not adhering to the above time limit will not be eligible for an award.
Authors are responsible for dismantling their posters after the congress. The congress organizers do not take responsibility for posters that are not removed after the scheduled poster dismantling time. Forgotten posters will not be mailed after the congress.
Angusta® The only approved oral medicinal 43 product for induction of labor
Women prefer oral treatment1
25 mcg tablet with flexible dosing – freedom to individualize [email protected] Dual action – induces cervival ripening and uterine contractions www.azanta.com
Forkortet produktinformation.Afsnit markeret med stjerne * er omskrevet/forkortet i forhold til det af Lægemiddelstyrelsen godkendte produktresumé af 1. marts 2017, som kan rekvireres vederlagsfrit fra Azanta Danmark A/S, Gearhalsvej 1, 2500 Valby, eller som kan downloades fra www.produktresume.dk. Angusta 25 mikrogram tabletter indeholder 25 mikrogram misoprostol. Indikation: Angusta er indiceret til induktion af fødsel. Dosering og indgivelsesmåde*: Dosering: Den anbefalede dosis af Angusta er 25 mikrogram oralt hver 2. time eller 50 mikrogram oralt hver 4. time, i henhold til hospitalspraksis. Den maksimalt anbefalede dosis er 200 mikrogram over en 24-timers periode. Særlige populationer: Det bør overvejes at give en lavere dosis eller forlænge doseringsintervallerne til gravide kvinder med nyre- eller leverinsufficiens. Angustas sikkerhed og virkning hos gravide kvinder under 18 år er ikke blevet undersøgt. Administration: Administreres af oplært obstetrisk sundhedspersonale. Kontraindikationer*: Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne. Når fødslen er startet. Ved mistanke om eller påvisning af fosterpåvirkning før induktion (f.eks. negativ non-stresstest eller stresstest, mekonium-farvning eller diagnose eller anamnese med påvirket føtal status). Når oxytoksiske lægemidler og/eller andre lægemidler, som anvendes til induktion af fødslen, er givet. Ved mistanke om eller påvisning af ardannelse i uterus som følge af tidligere kirurgiske indgreb i uterus eller cervix, f.eks. kejsersnit. Ved anormalitet i uterus, som forhindrer vaginal fødsel. Ved placenta praevia eller ved vaginalblødning uden kendt årsag efter 24. svangerskabsuge. Ved føtal malpræsentation, som kontraindicerer vaginal fødsel. Hos patienter med nyresvigt (GFR <15 ml/min/1,73 m2). Særlige advarsler og forsigtighedsregler*: Kan forårsage kraftig stimulation af uterus. Ved langvarige eller svære uterine kontraktioner, eller ved klinisk bekymring for moderen eller barnet, skal der ikke administreres yderligere Angusta-tabletter. Ved præeklampsi bør påvisning af eller mistanke om fosterpåvirkning udelukkes. Der er vist en øget risiko for dissemineret intravaskulær koagulation efter fødslen hos patienter, hvis fødsel er blevet fysisk eller farmakologisk induceret. Der er ingen eller begrænsede kliniske data med misoprostol ved flerfoldsgraviditeter, samt hos kvinder, som har haft flere end 5 tidligere vaginalfødsler. Der er ingen eller begrænsede kliniske data med anvendelse af misoprostol før 37. graviditetsuge. Der er ingen eller begrænsede data med misoprostol hos gravide kvinder med en modificeret Bishop-score (mBS) >6. Interaktioner*: Samtidig anvendelse af lægemidler, som indeholder oxytocin, eller andre lægemidler, som bidrager til induktion af fødslen, er kontraindicerede. Der kan være en synergistisk/additiv virkning af misoprostol og oxytocin. Plasmakoncentrationerne af misoprostol er ubetydelige efter 5 halveringstider (3,75 timer). Det anbefales at vente 4 timer efter den sidste dosis af Angusta, før oxytocin administreres. Graviditet og amning*: Angusta må kun anvendes før 37. svangerskabsuge, hvis det er klinisk indiceret. Gravide kvinder, hvor fødslen induceres med Angusta, udsættes for et lavt misoprostol-niveau i en kort periode til allersidst i graviditeten. Derfor anses risikoen for toksicitet under graviditeten, herunder teratogenicitet, som værende ubetydelig. Amning kan starte 4 timer efter den sidste dosis af Angusta er administreret. Bivirkninger*: Meget almindelig (≥1/10): kvalme1), opkastning1), meconium i fostervandet, blødning postpartum2). Almindelig ( ≥1/100 til <1/10): diarré, kvalme1), opkastning1), uterin hyperstimulation3), blødning postpartum2), kuldegysninger, lav Apgar score4), unormal føtal hjerterytme5). Ikke almindelig ( ≥1/1,000 til <1/100): lav Apgar score4), unormal føtal hjerterytme5). Ikke kendt (kan ikke estimeres ud fra forhåndenværende data)6): svimmelhed, neonatale kramper, neonatal asfyksi, neonatal cyanose, pruritus, føtal acidose, præmatur placentaløsning, uterin ruptur. 1): Kvalme og opkastning var ”almindelig” med 25 mikrogram hver 2. time og ”meget almindelig” med 50 mikrogram hver 4. time. 2): Blødning postpartum var ”meget almindelig” med 25 mikrogram hver 2. time og ”almindelig” med 50 mikrogram hver 4. time. 3): Uterin hyperstimulation blev rappporteret både med og uden ændringer i føtal hjerterytme. 4): Lav Apgar score var ”ikke almindelig” med 25 mikrogram hver 2. time og ”almindelig” med 50 mikrogram hver 4. time. 5): Unormal føtal hjerterytme blev rapporteret i forbindelse med uterin hyperstimulation. 6): Bivirkninger, som blev rapporteret for compassionate-use programmet med fødeafdelinger i Danmark, Norge og Finland, hvor ca. 29.000 kvinder er blevet eksponeret for Angusta til induktion af fødslen. Overdosering*: I tilfælde af, at der optræder symptomer på overdosering (f.eks. kraftig uterin hyperstimulation, som forårsager langvarige eller kraftige veer), skal behandling med Angusta seponeres og behandling i henhold til lokale retningslinjer skal initieres. De mulige konsekvenser af uterin hyperstimulation omfatter forstyrrelser i den føtale hjerterytme og asfyksi, i disse tilfælde bør kejsersnit overvejes. Pakninger og pris: 8 tabletter. For dagsaktuel pris se venligst www.medicinpriser.dk. Udlevering: BEGR. Indehaver af markedsføringstilladelsen: Azanta Danmark A/S, Gearhalsvej 1, 2500 Valby. Senest opdateret: 20. marts 2017.
Ref. 1: BMJ, doi:10.1136/bmj.38729.513819.63 (published 2 February 2006) 015ANG-INT-2018
40424 Angusta Annonce ENG-DK 210x240.indd 1 18/05/2018 14.25 COMMITTEES Organising Committee
Bjarne Rønde Kristensen, Hanna Övermark, Congress President, Junior Doctor, Head of Department, Chief Consultant, Department of Gynaecology and Obstetrics, OUH Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark 44 Odense University Hospital, Denmark Poul Bak Thorsen, Lise Lotte Torvin Andersen, Ass. Professor, Consultant, Consultant, Department of Gynaecology and Obstetrics, OUH Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark Odense University Hospital, Denmark Stinne Holm Bergholdt, Annemette Wildfang Lykkebo, Specialist Registrar, post doc, Head of Department, Chief Consultant Department of Gynaecology and Obstetrics, OUH Department of Gynaecology and Obstetrics, Hospital Odense University Hospital/Hospital Little Baelt Little Baelt, Kolding, Denmark Kolding, Denmark
Britta Frederiksen-Møller Specialist Registrar, Department of Gynaecology and Obstetrics, OUH Secretariat Odense University Hospital/Hospital Little Baelt, Kolding, Denmark Annette List, Congress Secretary, Jan Stener Jørgensen, Professor, Consultant, Chairman of Karen Stellinger, the Scientific Committee Congress Secretary, OUH Odense University Hospital, Denmark
Dorethe Frydshou Munck, Specialist Registrar, Department of Gynaecology and Obstetrics, OUH Odense University Hospital/Hospital Little Baelt Kolding, Denmark Scientific Committee
Jan Stener Jørgensen, Professor, Chairman of the Scientific Committee, Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark
Christina Anne Vinter, Staff Specialist , Deputy Chairman Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark
Bjarne Rønde Kristensen, Mette Tanvig, Head of Department, Congress President, Specialist registrar, post doc, Department of Gynaecology and Obstetrics, Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark OUH Odense University Hospital/ Hospital Little Baelt Kolding 45 Pernille Ravn, Ass. Professor, Consultant, Martin Rudnicki, Department of Gynaecology and Obstetrics, Ass. Professor, Consultant, OUH Odense University Hospital, Denmark Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark Vibeke Rasch, Professor, Consultant, Associated member of the Scientific Committee: Department of Gynaecology and Obstetrics, Ulrik Schiøler Kesmodel, OUH Odense University Hospital, Denmark Professor, Department of Gynaecology and Obstetrics, Jens Fedder, Herlev Hospital, Denmark Professor, Consultant, Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark
Jan Blaakær, Professor, Consultant, Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark
Lene Sperling, Ass. Professor, Consultant, Department of Gynaecology and Obstetrics, OUH Odense University Hospital, Denmark INDUSTRY SUPPORTED SYMPOSIA
June 11th 2018 at 12:00 to 13:00. Location: Store Sal Intuitive Surgical: “Place of da Vinci in benign GYN” Speaker: Jan Persson “The experience of Sös in setting up their benign program in the last 2 years” Speaker: Malin Brunes
46 June 12th 2018 at 12: to 13:00 - I. Location: Store Sal What is the current status of ESMYA®? PRAC recommendation on ESMYA® - background, conclusion and next steps Speaker: Pablo Arriagada, Vice President, MD, Gedeon Richter /Preglem S.A. Moderator: Sven Skouby, Professor, MD, DMSc, Univertity of Copenhagen
June 12th 2018 at 12:00 to 13:00 - II. Location: Pro Musica Salen Current & future trends of OSCM* Hysterosalpingography in clinical practice” – Guerbet Fertility work-up in Denmark Speaker: Anja Pinborg Overview of Latest Evidence comparing Oil & Water-soluble contrast media in HSG practice Speaker: Ben Mol How & when to use OSCM* in HSG procedure? Speaker: Kim Dreyer
(*) OSCM: Oil Soluble contrast medium ®
19,5 MG LEVONORGESTREL
5 års svangerskabsforebyggelse
®
19,5 MG LEVONORGESTREL
5 års svangerskabsforebyggelse PRÆVENTION TIL FERTILE KVINDER I ALLE ALDRE
En 5-årig hormonspiral som er en videreudvikling af Bayers tidligere hormonspiraler Er præventionsmiddel med høj præventionseffekt for kvinder i alle aldre, uafhængig af om de har født eller ikke1
Hvorfor Kyleena? • Lille spiral (28x30mm) og tyndt indføringsrør1,2 - indsætningen kan være mindre smertefuld for kvinden og enklere for indsætteren3
• Lav hormondosis - kun 9 µg LNG/24 timer i gennemsnit over 5 år4 47 Ved udskiftning af Mirena - tilbyd en Kyleena
Kyleena giver forandringer i blødningsmønsteret og over tid øger frekvensen af amenorré og sjældne blødninger; frekvensen af forlænget, urelmæssig og hyppig blødning aftager. Ovariefunktionen forbliver normal og østradiol-niveauerne opretholdes, selv når brugerne har amenorré5
Indikation: svangerskabsforebyggelse i op til 5 år Referanser: 1. Kyleena SPC 06.03.2018 afsnit 5.1 2. Kyleena SPC 06.03.2018 afsnit 3 3. Gemzell-Danielsson K, Schellschmidt I, Apter D, A randomized, phase II study describing the efficacy, bleeding profile, and Bayer A/S, Arne Jacobsens Alle 13, 6 safety of two low-dose levonorgestrel-releasing intrauterine 2300 København S contraceptive systems and Mirena. Fertil Steril 2012;97:616-22. Tlf. 4523 5000 4. Kyleena SPC 06.03.2018 afsnit 5.2 5. Kyleena SPC 06.03.2018 afsnit 4.8 L.DK.MKT.03.2018.2373
Produktinformationen er forkortet i forhold til det af Lægemiddelstyrelsen godkendte produktresumé. Venligst læs det fulde produktresume (SPC) igennem inden ordination af Kyleena. Produktinformation Kyleena, intrauterint indlæg med sølvring og blå tråde. Deklaration: Indeholder 19,5 mg Levonorgestrel. Indikationer: Svangerskabsforebyggelse i op til 5 år. Kontraindi- kationer: Graviditet. Tilstedeværende genital infektion. Akut cervicitis eller vaginitis. Postpartum endometritis/ infektion efter abort < 3 måneder. Cervikale celleforandringer. Uterin eller cervial malignitet. Gestagen-sensitive tumorer, f.eks. brystcancer. Unormal uafklaret uterin blødning. Livmodermisdannelse inkl. fibromer, hvis de påvirker op- lægning eller udtagning. Akut leversygdom eller levertumor. Overfølsomhed for levonorgestrel eller hjælpestof se SPC pkt. 6.1 Særlige advarsler og forsigtighedsregler vedrørende brugen: Før oplægning skal kvinden informeres om fordele og risici ved Kyleena, herunder tegn og symptomer på perforation og risikoen for ektopisk graviditet. Migræne, fokal migræne med asymmetriske synsforstyrrelser eller andet der indikerer transitorisk cerebral iskæmi. Usædvanlig kraftig hovedpine. Icterus. Væsentlig blodtryksstigning. Svær arteriel sygdom evt. AMI. Graviditet og amning: oplægning er kontraindiceret under graviditet. Brugen ændrer ikke fremtidig fertilitet. Opstår graviditet under anvendelse bør ektopisk graviditet udelukkes. Behandling bør undgås de første 6 uger af amningen. Mælkens kvalitet eller kvantitet påvirkes ikke. Bivirkninger: Ændring i blødningsmønster i hovedreglen til mindre blødninger over tid. Hovedpine. Mave-/underlivssmerter. Depression. Migræne. Kvalme. Akne. Aloplecia. Blødningsændringer. Ovariecyster. Vulvovaginitis. Øvre genitale infektioner. Dysmenoré. Brystsmerter/ubehag. Helt eller delvis udstødning af indlæg. Udflåd. I sjældne tilfælde perforering af livmoderen ved oplægning. Interaktioner: Ingen kendte. Dosering: Bør oplægges i dagene efter menstruation eller i tilslutning til abort. Skal skiftes hvert 5. år. Pris Se medicinpriser.dk for dagsaktuelle priser. Udlevering: A. Ej tilskud. Indehaveren af markedsføringstilladelsen: Bayer AB, Box 606, Gustav III:s Boulevard 56, 16926 Solna Sverige SPC dato 06.03.2018. L.DK.MKT.10.2016.1777 Det sidst reviderede produktresumé kan frit rekvireres hos: Bayer A/S, Arne Jacobsens Allé 13, 6, 2300 København S tlf. 45235000
Ethyl ester of iodized fatty acids of poppy seed oil
The only oil-based contrast agent indicated for HSG 1-9
INFERTILITY EVALUATION
TUBAL UTERINE 48 IMAGING IMAGING
LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. Indications (**): This medicinal product is for diagnostic purpose only - Hysterosalpingography – Lymphangiography. Posology and method of administration (*): The volume to be administered (1-20 mL) depends on the particular requirements of the technique and the size of the patient. The administration should be carried out using a glass syringe. Lipiodol® Ultra fluid must not be administered by intravenous, intra-arterial or intrathecal route. The patient should be kept under observation for at least 30 minutes. Contraindications: Hypersensitivity to LIPIODOL® ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrage or bleeding – Hysterosalpingography during pregnancy or acute pelvic inflammation – Bronchography. Warnings and special precautions for use (*): There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days and usually of a transient nature: The dose should be adapted or the examination itself cancelled in patients with impaired lung function, cardiorespiratory failure or pre-exiting right-sided cardiac overload in particular elderly patients. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL® ULTRA-FLUID. Thyroid: Iodinated contrast media can cause hyperthyroidism or development of hypothyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and any thyroid exploration should be performed before radiological examination. Interaction with other medicinal products and other forms of interaction (*): Beta blockers, including ophthalmic formulations, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, Interleukin II. Interference with diagnostic tests: As LIPIODOL® ULTRA FLUID remains in the body for several months, thyroid diagnos- tic results can be falsified for up to two years after lymphography.. Fertility, pregnancy and lactation (*): LIPIODOL® ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL® ULTRA-FLUID must be used - Effects on ability to drive and use machines: The effects on ability to drive and to use machines have not been investigated - Undesirable effects (*) most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, spinal damage, cerebral embolism, retinal arterial embolism, lymphoedema aggravation, hepatic vein thrombosis, granuloma. Overdose (*): The total dose of LIPIODOL® ULTRA-FLUID administered must not exceed 20 mL - Pharmacodynamic proper- ties (*) Pharmacotherapeutic group: ATC code: V08A D01 Radiographic contrast media, iodinated, non-water soluble. Dispensing group(*): B. Presentation (**): 10 mL glass ampoule. Current price (*) is available at www.Medicinpriser. dk. Marketing authorization holder (*): Guerbet - BP 57400 - F-95943 Roissy CdG cedex – FRANCE. Information: tel: 33 (0) 1 45 91 50 00. Date of revision of Danish Summary of Product Characteristics: December 23, 2014. (*) For complete information please refer to the local Summary of Product Characteristics (SPC). Latest approved Danish SPC is available here: www.produktresume.dk. For a copy of the SPC, please contact Guerbet local representative: Vicare Medical A/S Kongevejen 150 B, 3460 Birkerod. (**) Indications, volumes and presentations may differ from country to country. Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities via www.Meldenbirvirkning.dk or to our local Guerbet representative. Countries in which HSG indication is registered: USA, Canada, Argentina, UK, Ireland, The Netherlands, Denmark, Turkey, South-Africa, Japan, Taiwan, Thailand, Australia & New Zealand. Not intended for US Healthcare Professionals. 1. Lindequist S et al. Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media-a randomized prospective study. Radiology. 1991 Apr;179(1):69-74. 2. Nunley WC Jr et al. Intravasation during hysterosalpingography using oil-base contrast medium--a second look. Obstet Gynecol. 1987 Sep;70(3 Pt 1):309-12. 3. Johnson NP et al. The FLUSH trial--flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial. Hum Reprod. 2004 Sep;19(9):2043-51. 4. Johnson NP et al. Lipiodol fertility enhancement: two-year follow-up of a randomized trial suggests a transient benefit in endometriosis, but a sustained benefit in unexplained infertility. Hum Reprod. 2007 Nov;22(11):2857-62. 5. Brent K et al. After the FLUSH trial: A prospective observational study of lipiodol flushing as an innovative treatment for unexplained and endometriosis-related infertility. Aust N Z J Obstet Gynaecol. 2006 Aug;46(4):293-7. 6. Mohiyiddeen L et al. Tubal flushing for subfertility. Cochrane Database Syst Rev. 2015 May 1;(5):CD003718. 7. Dreyer K et al. Oil-based or water-based contrast for hysterosalpingography in infertile
women. N Engl J Med. 2017 May 25;376(21):2043-52. 8. Izumi G et al. Oil-Soluble Contrast Medium (OSCM) for hysterosalpingography modulates dendritic cell and regulatory T cell profiles in the peritoneal cavity: a possible mechanism by which P18 071 LUF HSG - Denmark May 2018 Illustrations: Shutterstock OSCM enhances fertility. J Immunol. 2017 Jun 1;198(11):4277-84. 9. Decision Resources Group. AMR Imaging database. 2017. CONGRESS SUPPORTERS Ethyl ester of iodized fatty acids of poppy seed oil
The only oil-based contrast agent indicated for HSG 1-9 Gold Sponsors
INFERTILITY EVALUATION
TUBAL UTERINE IMAGING IMAGING 49
Silver Sponsor
LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. Indications (**): This medicinal product is for diagnostic purpose only - Hysterosalpingography – Lymphangiography. Posology and method of administration (*): The volume to be administered (1-20 mL) depends on the particular requirements of the technique and the size of the patient. The administration should be carried out using a glass syringe. Lipiodol® Ultra fluid must not be administered by intravenous, intra-arterial or intrathecal route. The patient should be kept under observation for at least 30 minutes. Contraindications: Hypersensitivity to LIPIODOL® ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrage or bleeding – Hysterosalpingography during pregnancy or acute pelvic inflammation – Bronchography. Warnings and special precautions for use (*): There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days and usually of a transient nature: The dose should be adapted or the examination itself cancelled in patients with impaired lung function, cardiorespiratory failure or pre-exiting right-sided cardiac overload in particular elderly patients. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL® ULTRA-FLUID. Thyroid: Iodinated contrast media can cause hyperthyroidism or development of hypothyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and any thyroid exploration should be performed before radiological examination. Interaction with other medicinal products and other forms of interaction (*): Beta blockers, including ophthalmic formulations, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, Interleukin II. Interference with diagnostic tests: As LIPIODOL® ULTRA FLUID remains in the body for several months, thyroid diagnos- tic results can be falsified for up to two years after lymphography.. Fertility, pregnancy and lactation (*): LIPIODOL® ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL® ULTRA-FLUID must be used - Effects on ability to drive and use machines: The effects on ability to drive and to use machines have not been investigated - Undesirable effects (*) most adverse effects Bronze Sponsors are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, spinal damage, cerebral embolism, retinal arterial embolism, lymphoedema aggravation, hepatic vein thrombosis, granuloma. Overdose (*): The total dose of LIPIODOL® ULTRA-FLUID administered must not exceed 20 mL - Pharmacodynamic proper- ties (*) Pharmacotherapeutic group: ATC code: V08A D01 Radiographic contrast media, iodinated, non-water soluble. Dispensing group(*): B. Presentation (**): 10 mL glass ampoule. Current price (*) is available at www.Medicinpriser. dk. Marketing authorization holder (*): Guerbet - BP 57400 - F-95943 Roissy CdG cedex – FRANCE. Information: tel: 33 (0) 1 45 91 50 00. Date of revision of Danish Summary of Product Characteristics: December 23, 2014. (*) For complete information please refer to the local Summary of Product Characteristics (SPC). Latest approved Danish SPC is available here: www.produktresume.dk. For a copy of the SPC, please contact Guerbet local representative: Vicare Medical A/S Kongevejen 150 B, 3460 Birkerod. (**) Indications, volumes and presentations may differ from country to country. Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities via www.Meldenbirvirkning.dk or to our local Guerbet representative. Countries in which HSG indication is registered: USA, Canada, Argentina, UK, Ireland, The Netherlands, Denmark, Turkey, South-Africa, Japan, Taiwan, Thailand, Australia & New Zealand. Not intended for US Healthcare Professionals. 1. Lindequist S et al. Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media-a randomized prospective study. Radiology. 1991 Apr;179(1):69-74. 2. Nunley WC Jr et al. Intravasation during hysterosalpingography using oil-base contrast medium--a second look. Obstet Gynecol. 1987 Sep;70(3 Pt 1):309-12. 3. Johnson NP et al. The FLUSH trial--flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial. Hum Reprod. 2004 Sep;19(9):2043-51. 4. Johnson NP et al. Lipiodol fertility enhancement: two-year follow-up of a randomized trial suggests a transient benefit in endometriosis, but a sustained benefit in unexplained infertility. Hum Reprod. 2007 Nov;22(11):2857-62. 5. Brent K et al. After the FLUSH trial: A prospective observational study of lipiodol flushing as an innovative treatment for unexplained and endometriosis-related infertility. Aust N Z J Obstet Gynaecol. 2006 Aug;46(4):293-7. 6. Mohiyiddeen L et al. Tubal flushing for subfertility. Cochrane Database Syst Rev. 2015 May 1;(5):CD003718. 7. Dreyer K et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017 May 25;376(21):2043-52. 8. Izumi G et al. Oil-Soluble Contrast Medium (OSCM) for hysterosalpingography modulates dendritic cell and regulatory T cell profiles in the peritoneal cavity: a possible mechanism by which P18 071 LUF HSG - Denmark May 2018 Illustrations: Shutterstock OSCM enhances fertility. J Immunol. 2017 Jun 1;198(11):4277-84. 9. Decision Resources Group. AMR Imaging database. 2017. DIRECTORY OF EXHIBITORS
At the website nfog2018.dk/exhibition-2 you can download the Exhibitors floorplan
GROUND FLOOR
BOOTH Sponsor/Exhibitor Number 1 Neovitalis ApS 1A MSD Denmark Aps (Merc) 2 Intuitive Surgical 3 Bayer A/S 4 Avia Pharma AB 5A 5B Guerbet 6 6A Aspen Pharma 7 FJORDBLINK Medical ApS 50 8 Gothia Medical AB 9 GE Healthcare Danmark A/S 10 Mölnlycke Health Care ApS 11 SCHMITZ u. Söhne GmbH & Co. KG 12 KARL STORZ SE & Co. KG 13 Gedeon Richter Nordics 14 Laerdal Medical 15 NordicCell Aps 16 Medexa Diagnostisk Service AB 17 Cook Medical 18 Pharmacosmos A/S 19 Merit Medical Systems AB FIRST FLOOR – FOYER
BOOTH 31 BD Sponsor/Exhibitor Number 32 PerkinElmer 20 KEBOMED A/S 33 NFOG2021 Reykjavik 21+23 Olympus Danmark A/S 33A EBCOG2020 22 Pierre Fabre Dermo-Cosmetique Nordic A/S 34 NFOG Textbook 24 Contura International A/S 35 Oscar Medtec AB 25 Natera, Inc. 35A Læger Uden Grænser 26+28 Azanta Danmark 36 Maternity Foundation 27 Boston Scientific Nordic AB 37 29 ObsteCare AB 38 Apgar A/S 30 GynZone Aps 39 Ferring 39A 40 TOSHSCAN Danmark 41 Applied Medical D.E.B.V. 42 OptiSafe
51 VENUE (FLOORPLAN) ODEON
52
2nd oor
Pr The Pro Musica Hall o Musica Salen (K2) 18 m 15 m
Lobby 3, Light well Light well Balcony
Wardrobe
Wardrobe Lobby 2
L ight well 6 m Light well Entrance Room D
8.25 m
6 m Room C
8.25 m
6 m
Room B
8.25 m
2nd oor
R Hansestau Chr r Room ant A istian 6 m
R eception
Bar
C onf Service C er ence
enter
Ele vator Entrance
Business C
enter Welcome to our lunch seminar. 12 June 12.00–13.00. Main auditorium. WHAT IS THE CURRENT STATUS OF ESMYA® ? ® PRAC recommendation on ESMYA – background, conclusion and next steps 53 Speaker: Pablo Arriagada, Vice President, MD, Gedeon Richter / Preglem S.A. Moderator: Sven O. Skouby, Professor, MD, DMSc, University of Copenhagen
Presently no new treatment courses of Esmya should be initiated, including patients on intermittent treatment that have completed the treatment courses.
Forkortet produktresumé for Esmya 5 mg tabletter (ulipristalacetat). Kønshormoner og modulatorer af genitalsystemet, progesteron-receptormodulatorer. ATC-kode: G03XB02. Indikationer: Præoperativ behandling af moderate til svære symptomer på uterusfibromer hos voksne kvinder i den fertile alder. Intermitterende behandling af moderate til svære symptomer på uterusfibromer hos voksne kvinder i den fertile alder. Kontraindikationer: Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne an- ført i punkt 6.1. Graviditet og amning. Genitalblødning af ukendt ætiologi eller af andre årsager end uterusfibromer. Liv- moder-, livmoderhals-, brystkræft og kræft i æggestokkene. Bivirkninger: Meget almindelige: Amenorré. Fortykket endo- metrium. Almindelige: Hovedpine. Vertigo. Abdominale smerter. Kvalme. Akne. Muskuloskeletale smerter. Hedestigninger. Bækkensmerter. Ovariecyste. Brystømhed/-smerter. Træthed. Vægtøgning. Ikke almindelige: Medicin-overfølsomhed. Angst. Følelsesmæssig forstyrrelse. Svimmelhed. Mundtørhed. Forstoppelse. Alopeci. Hudtørhed. Hyperhidrose. Rygs- merter. Urininkontinens. Uterin blødning. Metrorragi. Genitalt udflåd. Brystgener. Ødem. Asteni. Forhøjet blodkolesterol. Forhøjede triglycerider. Sjælden: Næseblod. Dyspepsi. Flatulens. Ruptur af ovariecyste. Hævelse af bryst. Hyppighed ikke kendt: Angioødem. Advarsler: Ulipristalacetat bør kun ordineres efter en omhyggelig diagnose. Graviditet skal udelukkes forud for behandlingen. Ved mistanke om graviditet før iværksættelse af et nyt behandlingsforløb skal der foretagesen graviditetstest. Samtidig brug af piller med progestagen alene, en progestagenspiral. eller kombinerede p-piller anbefales ikke. Selvom de fleste kvinder, som tager en terapeutisk dosis ulipristalacetat, har anovulation, anbefales en kontraceptionsmetode uden hormoner i forbindelse med behandlingen. Ulipristalacetat har en specifik farmakodynamisk virkning på endometriet. Reversibel forøgelse af endometriets tykkelse kan forekomme under behandling. Ved gentagen intermitterende behandling anbefales periodisk overvågning af endometriet, inkl. årlig ultralydsundersøgelse, der skal udføres efter tilbagevenden af menstruation i behandlingsfri periode. Behandlingsforløbene bør hver især ikke strække sig over mere end 3 måneder, da risikoen for uønskede virkninger på endometriet, hvis behandlingen fortsættes uden afbrydelse, ikke er kendt. Patienter skal informeres om, at behandling med ulipristalacetat normalt giver et væsentlig mindre blodtab under menstruationen eller amenorré inden for de første 10 dages behandling. Ulipristalacetat anbefales ikke til patienter med svært nedsat nyrefunktion, medmindre patienten monitoreres nøje. Ulipristalacetat bør ikke an- vendes til patienter med moderat eller svært nedsat leverfunktion, medmindre patienten monitoreres nøje. Brug til kvin- der med svær astma, der er utilstrækkeligt kontrolleret af orale glukokortikoider, frarådes. Interaktioner: Samtidig admi- nistration af ulipristalacetat og følgende lægemidler anbefales ikke: Hormonale kontraceptiva • Moderate eller potente CYP3A4-hæmmere • Potente CYP3A4-inducere • Progestagen (bør desuden ikke tages inden for 12 dage efter afslutning af ulipristalacetat-behandlingen). Ulipristalacetat og P-gp-substrater (f.eks. dabigatranetexilat, digoxin, fexofenadin) bør administreres med mindst 1,5 times mellemrum. Virkningen af lægemidler, der øger den gastriske pH, forventes ikke at være af klinisk relevans for den daglige administration af ulipristalacetat-tabletter. Dosering: Behandlingen består af én tablet på 5 mg, der skal tages oralt én gang dagligt i behandlingsforløb på op til 3 måneder. Behandlinger bør kun påbegyndes, når der har været menstruation. Det første behandlingsforløb bør starte i den første menstruationsuge. Genbehandlingsforløb bør tidligst starte i den første uge af den anden menstruation efter afslutning af det foregående behandlingsforløb. Den behandlende læge skal forklare patienten, at behandlingsfrie perioder er nødvendige. Gentaget intermitterende behandling er undersøgt for op til 8 intermitterende behandlingsforløb. Overdosering: Enkeltdoser på op til 200 mg og daglige doser på 50 mg i 10 på hinanden følgende dage blev indgivet hos et begrænset antal forsøgsper- soner, og der blev ikke rapporteret om svære eller alvorlige bivirkninger. Fertilitet, graviditet og amning: Ulipristalacetat er kontraindiceret under graviditet og amning. Ulipristalacetat vil sandsynligvis have en ugunstig interaktion med piller med progestagen alene, progestagenspiraler eller kombinerede p-piller, og derfor anbefales samtidig anvendelse ikke. Selvom de fleste kvinder, som tager en terapeutisk dosis ulipristalacetat, har anovulation, anbefales en kontracep- tionsmetode uden hormoner i forbindelse med behandlingen. Virkning på evnen til at føre motorkøretøj eller betjene maskiner: Ulipristalacetat kan i mindre grad påvirke evnen til at føre motorkøretøj eller betjene maskiner, eftersom der er observeret let svimmelhed efter indtagelse af ulipristalacetat. Pakningsstørrelser og pris: Alu-PVC/PE/PVDC blister. Pakke med 28 tabletter. Se www.medicinpriser.dk for aktuelle priser. Udleveringsgruppe: NBS. Tilskudsstatus: Generelt tilskud. Indehaver af markedsføringstilladelsen: Gedeon Richter Plc., Gyömr i út 19-21., 1103 Budapest, Ungarn. Produktresuméet er forkortet i forhold til det godkendte produktresumé. Det fuldstændige produktresumé kan vederlagsfrit rekvireres fra indehaveren af markedsføringstilladelsen eller findes på Det Europæiske Lægemiddelagenturs hjemmeside: http://www.ema.europa.eu/ema/ Dato for ændring af produktresuméet: 16/02/2018 Siden udstedelsen af markedsføringstilladelse for Esmya er der rapporteret om fire tilfælde af alvorlig leverskade og EMA foretager en gennemgang af gavnlige effekter og risici. For at beskytte Patienterne er følgende midlertidige foranstaltninger aftalt, indtil gennemgangen er afsluttet: behandling bør ikke initieres hos nye patienter eller patienter, som har afsluttet et tidligere behandlingsforløb. Hos patienter, som er i behandling med Esmya, skal leverfunktionen monitoreres mindst en gang om måneden og 2-4 uger efter afsluttet behandling. Hvis en patient viser tegn eller symptomer på mulig leverskade (kvalme, opkastning, smerter i højre hypokondrium, anoreksi, asteni, gulsot osv.), skal patienten undersøges omgående, og der skal måles leverfunktionstal. Patienter, som under behandling med Esmya udvikler transaminaseniveauer > 2 gange den øvre normalgrænse, skal afbryde behandlingen og monitoreres tæt.
Norra Stationsgatan 61, 113 43 Stockholm. Tel: +46 8 611 24 00 GERI_0139 I ESM-MAJ18-NOR-18108:1 Technology. Outcomes. Value. Elevate the possibilities with da Vinci® Surgery.
Innovation & Integration Training & Education Support & Analytics
Visit our booth to test drive our technology. 54
The da Vinci Xi and da Vinci X Surgical Systems are class 2b medical devices CE marked (CE 0543) under the European Medical Devices Directive (93/42/EEC) and manufactured by Intuitive Surgical, Inc. Refer to Instructions for Use before use. PN 1048645-EU Rev A 05/2018 SLEEP WELL In Odense there is ample hotel capacity to suit every taste and budget. The city’s layout makes it easy to meet up with other delegates when going out for a meal. Discussions and brief meetings are always just a short step away. Most hotels are situated within walking distance of the main train station connected to the airports.
Odense railway & bus station
CABINN Hotel Plaza Odense
Hotel Ansgar VENUE: ODEON & Radisson Blu H.C. Andersen Hotel
Ydes Hotel City Hotel Odense Hotel Windsor
5 min First Hotel Grand 55 10 min
Map showing accommodations in the city centre 5-10 min. walk from the venue. WORK CLOSER. REACH FURTHER. 41st Nordic Congress of Obstetrics and Gynecology Odense, June 10th to 13th 2018
56
Dear Friends and Colleagues! It is a great pleasure to welcome you to the 42nd NFOG Congress which will be held in Reykjavik, Iceland June 13 – 16th 2021. The congress venue will be Harpa, the new Concert Hall and Conference Centre, which is beautifully located in the heart of Reykjavik, overlooking the bay and close to the congress hotels. We urge you to follow us on the congress website where the scientific programme, speakers and social programme will be posted as they evolve. Come and enjoy the scientific programme as well as clinical, scientific and social networking in Europe´s northernmost capital. We look forward to seeing you in 2021! www.nfog2021.is